Almaty,almatyCity
Almaty,howeverGreaterforPatientsTreatedInAlmatyCity
Analogs,their5h-pyridoPyrrolizin-5-oneAnalogs
Analogs,theirPyrrolizin-5-oneAnalogs
Analytics,dataAnalytics
Appearance,643PercecntWithSignificantDifferenceBetweenWhites
Appearance,99PercecntAccuracyInTermsOfClassification
Appearance,accuracy
Appearance,accuracyOfLesionDetection
Appearance,accuracyScores
Appearance,appearance
Appearance,betterDiagnosticAccuracyThanFfdm
Appearance,case
Appearance,caseOf39-year-oldManPresentedToUsWithMultipleSuutaneousLesionsOverChest
Appearance,caseOf75-year-oldPatientWithDuctalInfiltratedCarcinoma
Appearance,caseRecords
Appearance,caseReport
Appearance,change
Appearance,characteristicExosomalTumorMarkers
Appearance,conclusion
Appearance,dataForAccuracy
Appearance,defectStudies
Appearance,diagnosisAccuracy
Appearance,diagnosticAccuracy
Appearance,difference
Appearance,differenceBetweenDifferentBreastCancerSubtypes
Appearance,goodDiagnosticAbility
Appearance,importanceOfNondestructiveTestingInDefectStudies
Appearance,inConclusionDownregulatedInBreastCancer
Appearance,inConclusionMajorHereditaryBreastCancerGenesIrrespectiveOfAgeAtDiagnosisInJapaneseWomen
Appearance,inConclusionPathogenicFeatureInPrimarySamples
Appearance,inConclusionStillNecessaryForAdoptionOfCtnAsRoutineClinicalBiomarkerInPatientsWithBreastCancer
Appearance,inNumericalSimulationsAccuratelyReconstructedWith90PercecntAccuracyUpToNoiseLevelOf50Percecnt
Appearance,interestingClassOfCompoundsWithVariedDegreesOfStructuralComplexity
Appearance,oneCase
Appearance,orderOfAppearanceFrequency
Appearance,percentageChangeInIncidenceRates
Appearance,receiverOperatingCharacteristic
Appearance,significantDifference
Appearance,surgicalAccuracy
Appearance,theirAbility
Appearance,theirAbilityOfPrognosisPredictionInTheirOriginallyTargetedPopulationsOfBreastCancer
Appearance,unusualCaseOfPtosis
Appearance,variedDegreesOfStructuralComplexity
Applicability,applicability
Applicability,clinicalApplicability
Applicability,clinicalApplicabilityOfOurMethodInBreastCancerImagingSetting
Aptamer,aptamerMf3
Aptamer,ssdnaAptamerMf3
Areola,everolimusSideEffects
Areola,haveAssociatedWithNippleAreolaComplexInvolvementInPatientsWithBreastCancer
Areola,itSideEffects
Areola,nippleAreolaComplexInvolvement
Areola,pulmonaryEverolimusSideEffects
Areola,severeSideEffects
Areola,sideEffects
Areola,sideEffectsOfBreastCancerTherapiesIncludingHotFlushes
Areola,surgicalOptionsIncludingPreservationOfNippleAreolaComplex
Areola,variablesPredictiveOfNippleAreolaComplexInvolvementInPatients
Articles,Articles
Autoantibodies,autoantibodies
Autoantibodies,roleOfAutoantibodiesInEarlyCancerDiagnosis
Baseline,assessedAtBaseline
Baseline,baselineSolubleSt-2Level
Baseline,baselineSt-2Level
Baseline,patientsWithReducedBaselineLvef
Baseline,proteomeScaleWithHighSelectivity
Baseline,reducedBaselineCardiacFunction
Baseline,reducedBaselineLvef
Behaviours,changesInHealthBehavioursAfterBreastCancerDiagnosis
Behaviours,healthBehaviours
Behaviours,positiveChangesInTheirHealthBehaviours
Behaviours,theirHealthBehaviours
Capillaries,bareCapillaries
Capillaries,capillaries
Carcinoma,Carcinoma
Carcinoma,inflammatoryCarcinoma
Cavernous,cavernousMalformation
Cavernous,cavernousMalformationInduction
Cavernous,twoCasesOfCavernousMalformationFormationYears
Chemical,AMD3100
Chemical,anastrozole
Chemical,aspirin
Chemical,baicalin
Chemical,bortezomib
Chemical,Cabergoline
Chemical,DDE
Chemical,DDT
Chemical,diindolylmethane
Chemical,estrogen
Chemical,estrogens
Chemical,melatonin
Chemical,omega3FattyAcids
Chemical,paclitaxel
Chemical,TAG72
Chemical,Tamoxifen
Chemical,vitaminD
Chemical,warfarin
Collision,assessmentOfImpactOfAdvancesInDiagnosisOfPatientsWithBreastCancer
Collision,collisionTumorWithBreastCancerMetastasis
Collision,familyImpact
Collision,greatClinicalImpactForTumorDiagnosis
Collision,impact
Collision,impactOfStableKnockdownOfSmarcad1OnHumanBreastCancerCellProgression
Collision,injury
Collision,mostFrequentlyDiagnosedTumorInWomenWorldwideWithSignificantImpactOnMorbidity
Collision,potentialImpact
Collision,potentialImpactOnFertilityAfterTreatment
Collision,recurrentWords
Collision,theirQuestionableImpactOnMortalityOnIncidenceOfAdvancedTumors
Collision,theyCanImpactOnQualityOfLifePresent
Collision,typeOfCollisionTumor
Complexes,dynamicSh2Domain-scaffoldingProteinComplexes
Complexes,dynamicSh2ProteinComplexes
Complexes,phosphotyrosineProteinComplexes
Complexes,phosphotyrosineRegulatedProteinComplexes
Complications,acuteComplications
Complications,complications
Complications,lateComplications
Complications,occasionalComplications
Complications,riskFactorsForLateComplicationsAssociatedWithTivapthere
Computer,Computer
Consensus,consensus
Consensus,consensusOnAssociationBetweenExposureToDdt
Contraception,20PercecntIncreasedRiskOfBreastCancerAmongCurrentHormonalContraceptionUsers
Contraception,contraceptionUse
Contraception,hormonalContraceptionUse
Covariance,covariance
Covariance,proposedCovariance
Craniotomy,craniotomy
Craniotomy,excision
Craniotomy,forPrecisionResectionUrgentInFieldOfDiagnosis
Craniotomy,incompleteExcisionOfMalignantTissues
Craniotomy,surgicalExcision
Craniotomy,surgicalExcisionWithRadiation
Craniotomy,surgicalImplantationReconstruction
Cytology,aspirationCytology
Cytology,breastCancerGenetics
Cytology,breastCancerGeneticsInKenya
Cytology,cytology
Cytology,fineNeedleAspirationCytology
Cytology,fine-needleAspirationCytology
Cytology,histology
Cytology,intraoperativeScrapeCytology
Cytology,invasiveLobularHistology
Cytology,mitochondrialMorphology
Cytology,morphology
Cytology,needleAspirationCytology
Cytology,surfaceMorphology
Derivatives,activeDerivatives
Derivatives,tripentoneDerivatives
Dioxide,carbonDioxideLaserTechnology
Disease,acromegaly
Disease,AD
Disease,advancedBreastCancer
Disease,AION
Disease,amenorrhea
Disease,anxiety
Disease,aromataseInhibitors
Disease,autoimmuneDiseases
Disease,boneLoss
Disease,boneTumors
Disease,brainMetastasis
Disease,breastCancer
Disease,breastCancerDiagnosis
Disease,breastCancerProgression
Disease,breastCancers
Disease,breastCancerStaging
Disease,breastCancerWisconsin
Disease,breastCarcinoma
Disease,breastCarcinomas
Disease,breastTumor
Disease,calvarialLesions
Disease,cancer
Disease,cancerGenomeAtlas
Disease,cancer-relateddeaths
Disease,cancers
Disease,carcinogenesis
Disease,carcinoma
Disease,cardiacInjury
Disease,cardiotoxicity
Disease,cervicalCancer
Disease,chestWallLesions
Disease,chorea
Disease,choreiformMovements
Disease,cleftLip/palate
Disease,CLP
Disease,collisionTumor
Disease,colorectalCancer
Disease,cowdenSyndrome
Disease,CS
Disease,cyanosis
Disease,cytotoxicity
Disease,death
Disease,ductalCarcinoma
Disease,dyspareunia
Disease,dysplasia
Disease,elevatedLesion
Disease,epigeneticDysregulation
Disease,erysipelatoidCarcinoma
Disease,erythema
Disease,fanconiAnemia
Disease,fibroadenoma
Disease,fibrosis
Disease,FIT
Disease,gastricCancer
Disease,GDM
Disease,heartFailure
Disease,hematologicalMalignancy
Disease,her-2PositiveBreastCancer
Disease,hereditaryDiffuseGastricCancer
Disease,hereditaryDisease
Disease,heterogeneousDisease
Disease,HT
Disease,Hyperprolactinemia
Disease,hyperthermia
Disease,hypoxia
Disease,inborn-likeErrorsOfMetabolism
Disease,infection
Disease,infertility
Disease,inflammatoryTumour
Disease,invasiveBreastCancer
Disease,invasiveBreastCarcinoma
Disease,invasiveDuctalCarcinoma
Disease,kaposiSarcoma
Disease,krukenbergTumors
Disease,localizedDisease
Disease,lungAdenocarcinomas
Disease,lungCancer
Disease,lungCancers
Disease,LVEF
Disease,lymphoma
Disease,macroprolactinomas
Disease,maleBreastCancer
Disease,malformation
Disease,malignancies
Disease,malignancy
Disease,malignantPleuralEffusion
Disease,melanoma
Disease,metastases
Disease,metastasis
Disease,metastasize
Disease,metastaticBreastCancer
Disease,metastaticDisease
Disease,micrometastasis
Disease,nausea
Disease,neoplasms
Disease,neurologicalDisorders
Disease,neuropathicPain
Disease,neuropathies
Disease,neuropathy
Disease,non-hodgkinLymphoma
Disease,non-smallCellLungCancer
Disease,NSCLC
Disease,obesity
Disease,OS
Disease,osteolyticLesion
Disease,overallSurvival
Disease,PA
Disease,pain
Disease,paraneoplasticNeurologicSyndromes
Disease,PCOS
Disease,pleuralMetastasis
Disease,pneumopathy
Disease,polycysticOvarySyndrome
Disease,pretermBirth
Disease,primaryBreastDiffuseLargeB-cellLymphoma
Disease,primaryTumor
Disease,Prolactinomas
Disease,RDD
Disease,seromaProduction
Disease,sexualDysfunction
Disease,superiorVenaCavaSyndrome
Disease,tataMemorialCancerHospital
Disease,tendinopathy
Disease,toxicity
Disease,triple-negativeBreastCancer
Disease,triple-negativeBreastCancers
Disease,tumor
Disease,tumors
Disease,tumour
Disease,tumours
Disease,UC
Disease,upperGastrointestinalCancers
Disruption,disruption
Disruption,intrinsicDisruption
Disruption,perturbation
Disruption,postponementVisiting
Distance,boneDensity
Distance,breastImageneologicalSurveillanceBeginningAtAge
Distance,characteristicsInsideTumors
Distance,date
Distance,density
Distance,eConcentration
Distance,first
Distance,firstCaseOfGaslessRobot-assistedNipple-sparingMastectomyInPatientWithEarlyBreastCancer
Distance,firstDataOnPre-diagnosisConcentrationsOfSrankl
Distance,firstDose
Distance,firstFiveFacebookOpenBreastCancerGroupsInYear2016
Distance,firstPatientsWithPathologicallyTumor-freeNodes
Distance,firstSymptom
Distance,firstTime
Distance,firstTimeIn1984
Distance,firstYearsAfterWithdrawal
Distance,focalAsymmetricDensity
Distance,haveReportedForFirstTimeInCaninesInStudy
Distance,itsFirstDescription
Distance,shouldIdeallyAdministeredAtLeast1WeekBeforeCommencementOfAlkylatingTreatment
Distance,sinceItsFirstDescriptionAtInstituteOfPathologyInKielAgoHasShown
Distance,totalHemoglobinConcentration
Distance,veryRareClinicalEntityWithOnlyFewCasesHavingReportedToDate
Disturbances,sleepDisturbances
DNA,aberrantDnaMethylation
DNA,abnormalDnaMethylation
DNA,dnaDamage
DNA,dnaMethylation
DNA,dnaMethylationDifferencesBetweenTumorBreastTissue
DNA,involvedInDnaDamageRegulation
Document,associationBetweenNsaidsExposureInFemalePatientsWithAd
Document,balfContent
Document,balfContentOfProgranulinIn46NsclcPatientsBeforeChemotherapy
Document,content
Document,copyright
Document,coxModel
Document,ddtExposure
Document,detectionRateOfMutationsHigherThanThatDescribedInLiterature
Document,document
Document,estrogenicExposure
Document,exponentialTiltingSemiparametricModelAccountForNonignorableMissingDataMechanism
Document,exposure
Document,form
Document,formOfApoptosis
Document,higherBalfContent
Document,improvedDiagnosticContentOverEx-vivoClinicalMammographyImagesAtLowerDose
Document,limitedLiterature
Document,literature
Document,literatureForFamiliesWithCdh1Mutations
Document,model
Document,model2
Document,modelAccount
Document,mouseModel
Document,nomogram
Document,nsaidExposure
Document,nsaidsExposure
Document,nudeMouseModel
Document,ourLiteratureReview
Document,papers
Document,questionnaireBasedOnAnderson'SdelayModel
Document,randomEffectsModel
Document,similarToThatReportedInLiterature
Document,thatReportedInLiterature
Document,threePapers
Document,zebrafishTumorModel
Drugs,cardiotoxicityOfHer2-targetedDrugs
Drugs,chemotherapyDrugs
Drugs,conventionalChemotherapyDrugs
Drugs,developmentOfEffectiveDrugsForTreatmentOfHormone-dependentBreastCancer
Drugs,developmentOfNewDrugs
Drugs,drugs
Drugs,resistanceToAntimitoticDrugs
Drugs,usedDrugs
Dysplasia,binaryLogisticRegressionModels
Dysplasia,coxRegressionAnalyses
Dysplasia,finalMultipleRegressionModel
Dysplasia,kaplan-meierRegressionMethods
Dysplasia,multivariableLogisticRegressionAnalysis
Dysplasia,penalizedLogisticRegression
Dysplasia,regression
Dysplasia,regressionAnalysis
Dysplasia,regressionModel
Dysplasia,regressionModels
Dysplasia,zero-inflatedPoissonRegression
Endocrine,adjuvantEndocrineHormonalTherapy
Endocrine,amongOlderAdultsObservedForBreastCancerInFemalesForProstateCancerInMales
Endocrine,antihormonalTherapyForHormoneReceptor-positiveBreastCancer
Endocrine,canEffectivelyTreatedByEndocrineTherapy
Endocrine,commonEndocrineDisorder
Endocrine,commonlyUsedAntihormonalTherapyInTreatmentOfBreastCancerInPostmenopausalWomenSpecificallyInTreatmentOfHormoneReceptor-positiveBreastCancer
Endocrine,dealingWithEndocrineResistanceInPatientsWithBreastCancer
Endocrine,earlyDetectionOfProstateCancer
Endocrine,endocrineResistance
Endocrine,evidenceForEfficacyOfGonadotropin-releasingHormoneAgonists
Endocrine,gonadotropin
Endocrine,hormoneReceptor-positiveBreastCancer
Endocrine,hormoneReceptor-positiveTumors
Endocrine,humanChorionicGonadotropin
Endocrine,imagingOfProstate
Endocrine,largeCohortOfPatientsWithPituitaryAdenomasInOutpatientClinic
Endocrine,menopausalHormoneTherapy
Endocrine,patientsWithProstateCancer
Endocrine,pituitaryFunction
Endocrine,prostateCancerSurvivors
Endocrine,termsOfProlactinNormalizationInPituitaryFunction
Endocrine,thanFamiliesOfPatientsWithNon-functioningPituitaryAdenomas
Endocrine,treatmentOfHormoneReceptor-positiveBreastCancer
Erythematous,boundErythematousAppearance
Erythematous,characterizedByAcuteAppearanceWithErythematousPlaqueSometimesHotMoreOftenSituatedInPrimaryTumorVicinity
Ethanolic,freshLeafEthanolicExtract-treatedMda-mb-231Cells
Exosomes,ca125-richExosomes
Exosomes,circulatingExosomes
Exosomes,exosomes
Exosomes,exosomesCk19
Exosomes,exosomesDerivedCk19
Exosomes,exosomesOf5-fu-resistantCrcCellsInThoseOfHighMetastaticCrcCells
Exosomes,isolatingExosomes
Exosomes,problemOfDiscriminationOfExosomes
Exosomes,tumorInterstitialFluidDerivedExosomes
Exposure,betterPredictionPerformance
Exposure,discovery
Exposure,enlargement
Exposure,equivalentPerformance
Exposure,excellentPerformance
Exposure,finiteSamplePerformanceOfProposedMethods
Exposure,goodDiagnosticPerformance
Exposure,hemorrhagicEnlargement30YearsAfter
Exposure,highestPerformance
Exposure,itsDiagnosticPerformance
Exposure,itsPerformance
Exposure,limitedPerformanceForWomenWithDenseBreasts
Exposure,performance
Exposure,performanceEvaluation
Exposure,reportOnPerformanceOfBayesClassifiersLikeTreeAugmentedNaiveBayes
Extract,average
Extract,averageOf425±496Ctcs/2Ml
Extract,averageOfFiveInvolvedSites
Extract,averageRisk
Extract,benefit
Extract,benefitOfProtectionAgainstCardiovascularEventsWithPotentialReductionInBreastCancerRisk
Extract,cause
Extract,clearEvidenceForbenefitsOfTanUsageInBreastCancerClassification
Extract,commonCause
Extract,commonCauseOfMorbidity
Extract,complementaryBenefit
Extract,cssBenefit
Extract,freshLeafEthanolicExtract
Extract,highFreshLeafEthanolicExtractConcentrations
Extract,leafExtract
Extract,mostCommonExtrinsicCause
Extract,mostFrequentCause
Extract,mostImportantCause
Extract,mostProminentCause
Extract,treatmentBenefitWithTrastuzumabTherapyForBreastCancer
Extract,womenOfAverageRiskWithDenseBreasts
Extracts,leafExtracts
Extracts,pseuderanthemumPalatiferumRadlkExtracts
Food,assay
Food,atEndOfFollow-upClassifiedRegardingTheirAdherenceToRecommendationsForCancerPrevention
Food,betterAccessToAtertiaryCancerCenter
Food,cancerCareCenter
Food,cellCultureSupernatants
Food,coreNeedleBiopsy
Food,differencesInAssayPerformance
Food,differentContrastAgent
Food,documentedAsImportantTumor-promotingAgentForSeveralHumanCarcinomasIncludingBreastCancer
Food,education
Food,experience
Food,expressionOfItsTargetProteinCytokine-inducedApoptosisInhibitor1
Food,followedFromDateOfFirstDiagnosisOfAdToEndOf2013
Food,foodRecommendations
Food,furthermoreCouldDevelopedAsPotentialTherapeuticAgentAgainstMcf7-cell-related
Food,goal
Food,heartFailureParticularly
Food,henceMajorResearchGoal
Food,hotIssue
Food,hotIssueInFieldOfCancerClassification
Food,impairedBaselineCardiacFunctionExperience
Food,issue
Food,itParticularlyAttractiveAsPotentialAgentInBreastCancerPrevention
Food,kernelApproach
Food,mtorInhibitorEverolimus
Food,multiplexAssay
Food,multiplexedAssayForDetectionOfAutoantibodiesInCanineTumours
Food,ourExperience
Food,ourExperienceOfHigh-doseRadiotherapy
Food,patientEducationIdentification/reportingOfSideEffects
Food,potentialOfAionAsEffectiveMultimodalContrastAgentForBreastCancerDiagnosis
Food,rural-basedTertiaryCancerCareCenter
Food,specificFoodRecommendations
Food,symptomaticHeartFailure
Food,toEndDevelopedWithDrugToAntibodyRatioOf329
Functionality,functionality
Functionality,oncogenicFunctionality
Functionality,oncogenicFunctionalityOfSpc24InBreastCancerProgression
Gene,BRCA1
Gene,BRCA1/2
Gene,BRCC3
Gene,CK19
Gene,CK5
Gene,CXCR4
Gene,DESI-MSI
Gene,Drp1
Gene,ERBB2
Gene,ESR1
Gene,FOXC1
Gene,FXYD3
Gene,growthHormoneReceptor
Gene,HER2
Gene,HR
Gene,Mfn1
Gene,microRNA-22
Gene,miR-10a
Gene,MORC4
Gene,NCAM1
Gene,p27
Gene,PALB2
Gene,PAX8
Gene,PCDH10
Gene,Period2
Gene,Progranulin
Gene,Protocadherin-10
Gene,RANKL
Gene,SMARCAD1
Gene,SOX9
Gene,SPC24
Gene,TP53
Gene,TTF-1
Gene,VAP-1
Gene,vascularAdhesionProtein-1
Gene,VDR
Gene,VEGF-D
Glycosylation,glycosylation
Glycosylation,glycosylationOfMembraneTypeMr
Glycosylation,sixGlycosylationSites
Granuloma,EosinophilicGranuloma
Granuloma,Granuloma
Granuloma,neuroma
Granuloma,traumaticNeuroma
Granuloma,veryRareCaseOfTraumaticBreastNeuroma
Guidelines,guidelines
Guidelines,internationalGuidelines
HER-2,adultsWithHer-2PositiveBreastCancer
HER-2,caseOfWomanOnNeratinibForHer-2PositiveInfiltratingDuctalCarcinoma
Hyperglycemia,cell-killingEffect
Hyperglycemia,cell-killingEffectInTriple-negativeSubtypeMda-mb-231Cells
Hyperglycemia,effect
Hyperglycemia,effectOfBaicalinInBreastCancer
Hyperglycemia,effectOfDdtSpraysOnBreastCancerIncidenceRate
Hyperglycemia,effectOfSex
Hyperglycemia,effectOnBoneRemodelingThroughItsReceptor
Hyperglycemia,highlyProblematicDose-limitingEffect
Hyperglycemia,hyperglycemia
Hyperglycemia,managedWithPalliativeRightHemicolectomyInViewOfConstipationAsSystemicTreatment
Hyperglycemia,novelStrategiesForDiagnosisOfBreastCancerWithHyperglycemia
Images,featuresFromImages
Images,high-resolutionImages
Images,images
Images,increasedContrast-to-noiseRatioForMonochromaticOverClinicalImagesForWell-definedPhantom
Images,mammographicImages
Images,microscopicImages
Images,opticalCoherenceTomographyImages
Images,virtualRecombinedImagesFromLeImages
Incidence,incidenceRates
Incidence,incidenceTrendPlots
Incorporation,amongThemNewlyIdentifiedInStudy
Incorporation,associationsBetweenChangeOfPerceivedWorkAbility
Incorporation,associationStudy
Incorporation,case-controlAssociationStudyForVariantsInCodingRegionsOf11HereditaryBreastCancerGenesIn7051UnselectedBreastCancerPatientsOfJapaneseAncestry
Incorporation,chicagoStudy
Incorporation,cohortStudy
Incorporation,cross-sectionalStudy
Incorporation,descriptiveStudy
Incorporation,experimentalStudyOfCryo-stabilityOfCancerCells
Incorporation,followingStudy
Incorporation,includedInStudy
Incorporation,incorporation
Incorporation,inPresentStudyConductedBetweenMcf-7Tamoxifen-resistantLcc2CellLines
Incorporation,inPresentStudyPerformedFor9Features
Incorporation,inPresentWorkHasProposedForBreastCancerDiagnosis
Incorporation,inStudyDevelopedByCell-selex
Incorporation,inStudyDevelopedForHighlyEfficientIsolationOfCtcsFromBreastCancerPatients
Incorporation,inStudyFusedWithMouseMyelomaCellLineSp2/0InPresence
Incorporation,multicenterStudy
Incorporation,ourPreviousWorkRegardingToPropertiesOfPluronicsWithDifferentPhotosensitizerForPhotodynamicTherapy
Incorporation,ourStudy
Incorporation,perceivedWorkAbility
Incorporation,presentedWorkForFeatureExtraction
Incorporation,presentStudy
Incorporation,prospectiveNestedCase-controlStudy
Incorporation,recentDanishCohortStudy
Incorporation,resultsOfStudy
Incorporation,retrospectiveObservationalStudyOf264Her2-positiveAdvancedBreastCancer
Incorporation,retrospectiveStudyOfPatientsWithCa-vte
Incorporation,retrospectiveStudyOfWomenTreatedWithTrastuzumabForHumanEpidermalGrowthFactorReceptor2BreastCancerAtMayoClinicBetweenJanuary12000
Incorporation,ronInternalization
Incorporation,study
Incorporation,studyObjective
Incorporation,study'sObjectives
Incorporation,third-lineTreatmentForAdvancedTriple-negativeBreastCancerthisRetrospectiveStudy
Incorporation,transferLearning
Incorporation,two-yearStudy
Incorporation,workAbility
Individuals,Individuals
Infrared,infraredFluorescentDye
Infrared,infraredFluorescentImagingInTripleNegativeInVitro
Infrared,mildUvLight
Infrared,moreResearchLight
Infrared,nirLight
Infrared,researchLight
Infrared,secondaryConfirmationOfSignalAccumulationUsingNearInfraredFluorescentImaging
Inhibition,Inhibition
Interference,assessment
Interference,chronicDebilitatingLifelongComplication
Interference,complication
Interference,delivery
Interference,disposition
Interference,drugDeliveryStrategies
Interference,evenLessFrequentComplication
Interference,finalAssessment
Interference,intervention
Interference,interventionArm
Interference,itsWidespreadImplementation
Interference,mostFrequentLateComplication
Interference,newerDrugDeliveryStrategies
Interference,postAssessment
Interference,postOperativeAssessment
Interference,preoperativeAssessment
Interference,pre-operativeAssessment
Interference,rareComplicationMostCommonlySeenInPatientsPreviouslyTreatedForBreastCancer
Interference,scalableIntervention
Interference,shouldEstablishedBetweenScreeningWithImplementationOfRobustQualityAssurance
Interference,theirBeliefsRegardingCancerCausation
Interference,theory-basedIntervention
Interference,tripleAssessmentFollowed
Interference,urgentlyAdvanceImplementation
Interval,absence
Interval,after6Months'TherapySignificantlyHigherIn3rdTertiaryGroup
Interval,axillaryClearance
Interval,cellCycleArrestFollowedByMassiveCellDeath
Interval,cellCycleRegulators
Interval,chineseExpertGroup
Interval,controlGroup
Interval,correspondingHistologyImage
Interval,cycle
Interval,energyImage
Interval,enhancementOfImage
Interval,excellentPerformanceInFieldOfMedicalImagesDiagnosis
Interval,field
Interval,fieldOfBreastCancerDetection
Interval,fieldOfCancerClassification
Interval,fieldOfMedicalImagesDiagnosis
Interval,g1/s-phaseCellCycleArrest
Interval,group
Interval,group1
Interval,group2
Interval,groupProfilesForSubgroup
Interval,highestSeInTotalGroup
Interval,highlyDiverseGroupOfMalignantNeoplasiaWithPoorOutcome
Interval,image
Interval,imageQuality
Interval,imageSegmentation
Interval,increasingCellCycleGeneExpression
Interval,interval
Interval,intervalBetweenDiagnosis
Interval,key
Interval,keyCircadianClockGene
Interval,keyHypomethylationSites
Interval,keyRole
Interval,latencyPeriod
Interval,latencyTime
Interval,longPeriodOfTime
Interval,meanwhileBetterThanInCapecitabineGroup
Interval,medianFollow-upPeriod
Interval,medianInterval
Interval,medianLatencyPeriod
Interval,medianLatencyTime
Interval,note
Interval,observedInTransfectionGroup
Interval,overPeriod2008-2012RegisteredInOlderAdultsInFourPopulations
Interval,period
Interval,periodFromApril2012ToDecember2017
Interval,postmenopausalPeriodWithDopamineAgonists
Interval,preliminaryGroupOfCtibl
Interval,state-of-the-artImageAnalysisMethods
Interval,thanCapecitabineGroup
Interval,totalGroup
Interval,tumorNippleDistance
Interval,youngerAgeGroup
Isolation,clinicalFeasibilityOfCtcIsolation
Isolation,ctcIsolationTechniques
Isolation,feasibleCtcIsolationTechniques
Issues,changesToIntimateIssuesIncludingSexualHealth
Issues,issues
Issues,issuesOfExistingContrastAgents
Issues,issuesRelatedToTherapeuticSequencingInLocalTherapyOfBreastCancer
Late-stage,late-stage
Late-stage,late-stageCancerDiagnosis
Late-stage,risksOfLate-stageDiagnosis
Lifestyle,diagnosisOfResponseToTreatment
Lifestyle,influenceOfLifestyleFactorsOnPrognosis
Lifestyle,itsWater-bathSetup
Lifestyle,lifestyleFactors
Lifestyle,mitochondrialResponse
Lifestyle,objectiveResponseRate
Lifestyle,oxphosTranscriptionalResponse
Lifestyle,proposedTotal-variationSchemeWithSpatially-varyingAnisotropicWeightingCompensateForGeometricBiasFromLimitedAngleImagingSetup
Lifestyle,response
Lifestyle,responseFollowingAdministrationOfNeoadjuvantChemotherapy
Lifestyle,responseRate
Lifestyle,signature
Lifestyle,subtype-specificSignature
Lifestyle,three-lncrnaSignature
Literacy,definitionOfHealthLiteracy
Literacy,influenceOfHealthLiteracyOnPathwayToCancerDiagnosis
Literacy,lowHealthLiteracy
Lymphedema,developmentOfLymphedema
Lymphedema,higherProportionOfPatientsWithLymphedema
Lymphedema,lymphedemaPatients
Lymphedema,outcomeInLymphedemaPatients
Lymphedema,secondaryLymphedema
Lymphedema,unilateralBreastCancer-relatedLymphedema
Macroadenomas,macroadenomas
Macroadenomas,usuallyMacroadenomas
Malformation,malformationInduction
Mammographic,Mammographic
Markers,adequateSampleForAnalysisOfMolecularMarkersToGuidePatientsWithNon-smallCellLungCancerToAppropriateTargetedTherapies
Markers,diagnosticValueOfMarkers
Markers,epigeneticMarkers
Markers,estrogen-receptorAmongOtherMarkers
Markers,immunohistochemicalMarkers
Markers,markers
Markers,markersOfMesothelioma
Markers,mightCrcMarkers
Markers,mightMetastaticCrcMarkers
Markers,solubleMarkers
Markers,specificMethylationMarkersImportantForCrcDetection
Markers,standardMethodForEvaluationOfProposedPrognosticTumourMarkers
Markers,theirRelatedMarkersAtDifferentPointsOfChemotherapyRegimensInMetastaticBreastCancer
Markers,tumorMarkers
Mastectomies,bilateralMastectomies
Mastectomies,bilateralTotalMastectomies
Mastectomies,mastectomies
Membrane,antibodyPanel
Membrane,atrophiedVaginalMucosa
Membrane,combinedPanel
Membrane,membraneTypeMannoseReceptor
Membrane,membraneTypeMr
Membrane,panel
Membrane,paraneoplasticAntibodyPanel
Metformin,metformin
Metformin,metforminTreatment
Microenvironment,fundamentalComponentsOfTumorMicroenvironment
Microenvironment,imbalanceInCytokineProfilesInPro-tumorigenicMicroenvironment
Microenvironment,pro-tumorigenicMicroenvironment
Modulators,associationBetweenUseOfSelectiveEstrogenReceptorModulators
Modulators,protectiveEffectOfAspirinForCardiovascularEventsDuringItsConcomitantUseWithSelectiveEstrogenReceptorModulatorsInPreventionOfBreastCancer
Modulators,selectiveEstrogenReceptorModulators
Mortality,mortalityRates
Mother,absorptionImagesAcquiredWithMonochromaticX-raysFromCompactSynchrotronSourceBasedOnInverseComptonScattering
Mother,acuteDangerToMother
Mother,conflictBetweenCareOfMother
Mother,mustIndividualizedWithEmphasisOnOptimalCareOfMother
Mother,prominentSourceOfCancerMortalityInWomenThroughoutWorld
MSOT,MSOT
MSOT,msotImaging
Mutation,rs5743810
Mutations,Mutations
Nanoplatform,especiallyModifiedOntoSurfaceOfNanoplatformForActiveHer2-targing
Nanoplatform,nanoplatform
Nanoplatform,skeletonOfNanoplatform
Nanoplatform,theranosticNanoplatform
Neuromas,breastNeuromas
Neuromas,only35CasesOfTraumaticBreastNeuromas
Neuropathy,18-fdgFlux
Neuropathy,adhesionProtein-1
Neuropathy,chemotherapy-inducedNeuropathy
Neuropathy,commonPrimaryLesion
Neuropathy,generallyFibrosis
Neuropathy,infiltrativeLesion
Neuropathy,irregularHyperintenseLesion
Neuropathy,irregularHyperintenseLesionInT2InLeftParietalRegion
Neuropathy,lesion
Neuropathy,mayIndicativeOfBenignLesion
Neuropathy,patientsWithHistoryOfTranstuzumab-inducedCardiacDysfunction
Neuropathy,poorAdhesion
Neuropathy,possibilityOfEarlyDetectionOfRiskOfOsteoporosisToItsDevelopment
Neuropathy,preventionOfChemotherapy-inducedNeuropathy
Neuropathy,relationToOccurrenceOfOsteoporosisAmongVariousEthnicGroups
Nondestructive,byWhichObservedInNondestructiveWayThroughThermalAnalysis
Nondestructive,mostNondestructiveTests
Nondestructive,nondestructiveTesting
Nondestructive,nondestructiveTests
NSAID,nsaidUsers
NSAIDs,NSAIDs
Obstacle,adjustedHazardRatio
Obstacle,barrierFunction
Obstacle,block
Obstacle,blockade
Obstacle,brcc3Interference
Obstacle,catheter-relatedObstruction
Obstacle,collectionOfSignsResultingFromObstructionOfSuperiorVenaCavaIncludingSwellingOfUpperBodyOfHead
Obstacle,coxHazardRegressionAnalysis
Obstacle,coxHazardRegressionModels
Obstacle,coxProportionalHazardModel
Obstacle,coxProportionalHazardRegressionModels
Obstacle,hazardRates
Obstacle,hazardRatiosWith95PercecntConfidenceIntervals
Obstacle,lowerCumulativeHazardRates
Obstacle,majorObstacle
Obstacle,majorObstacleInTreatmentOfTriple-negativeBreastCancerWithConventionalChemotherapeuticAgents
Obstacle,multivariateCoxProportionalHazardRegressionAnalysis
Obstacle,obstacle
Obstacle,obstruction
Obstacle,summaryHazardRatios
Obstacle,thusWouldCrucialForApplicationOfPreventiveStrategies
Oestrogen,oestrogenReceptorAlpha
Other,-916
Other,-1
Other,0.00001
Other,0.0001
Other,0.001
Other,0.003
Other,0.007
Other,0.011
Other,0.02
Other,0.021
Other,0.029
Other,0.32
Other,0.46
Other,0.84
Other,1
Other,4
Other,4.71
Other,13
Other,18.791
Other,19
Other,20
Other,26
Other,40
Other,50
Other,77
Other,80
Other,408
Other,700
Other,1984
Other,2002
Other,2007
Other,9398
Other,Jan-90
Other,+239Percecnt
Other,0-5Years
Other,100000Person-years
Other,1000Patients
Other,100Patients
Other,107ObservationalStudies
Other,10Centers
Other,10Countries
Other,10-foldCross-validation
Other,10Mg/kg
Other,10NeedContents
Other,10Percecnt
Other,10-yearBreastCancerSurvival
Other,11BreastRadiologists
Other,11Days
Other,11HereditaryBreastCancerGenes
Other,120BreastCancerPatients
Other,120Patients
Other,12-15Percecnt
Other,12404Patients
Other,125DogSeraSamplesIncluding75MammaryTumourSera
Other,12EventsAmong121Patients
Other,12SampledWomen
Other,133BreastCancerCases
Other,133Controls
Other,138Patients
Other,13-hDailyOvernightFast
Other,13Percecnt
Other,13PercecntOfDeaths
Other,1444Women
Other,145Percecnt
Other,14644Patients
Other,15Percecnt
Other,160Patients
Other,16PrimaryBreastCancers
Other,1722Comments
Other,17Years
Other,182Percecnt
Other,186Pathology-provenS
Other,186S
Other,18FemaleNudeMice
Other,18f-fluoro-deoxy-glucoseCombined
Other,192Months
Other,195Years
Other,1973To2014
Other,1999-2011
Other,1H
Other,1Year
Other,1YearTo5Years
Other,2/149
Other,2060Women
Other,20BreastCancerPatients
Other,20PercecntForGata3
Other,20-year-oldWoman
Other,21Months
Other,21Percecnt
Other,22Deaths
Other,22Patients
Other,23Patients
Other,23Studies
Other,2-3Years
Other,240Months
Other,240MonthsWith1SurvivalRateOf707PercecntRespectively
Other,244GermlinePathogenicVariants
Other,244GermlineVariants
Other,252Percecnt
Other,255Months
Other,25-year-oldWoman
Other,26/31
Other,2651StudiesIdentified
Other,26894Ca-vtePatientsTreatedWithAnticoagulants
Other,26894People
Other,27-36MillionPatients
Other,27b
Other,27PerCentOfPatients
Other,28Segments
Other,2921Posts
Other,2IndependentCohorts
Other,2Patients
Other,30Cm
Other,30DoublingTimesNecessary
Other,30TBreastMagneticResonanceImagingExaminations
Other,32620MatchedPatientsWithoutPcos
Other,35-64Years
Other,375Percecnt
Other,38Months
Other,3Malignancies
Other,3PreviousMalignancies
Other,3-timeAssessments
Other,40Percecnt
Other,414Percecnt
Other,417Percecnt
Other,4248BreastCancerPatients
Other,428BreastCancerPatients
Other,44Percecnt
Other,464Percecnt
Other,466Percecnt
Other,46NsclcPatientsBeforeChemotherapy
Other,481Women
Other,48Years
Other,49CedmCasesCollectedFromMayoClinic
Other,49Patients
Other,4Domains
Other,505Percecnt
Other,505PercecntOfAnalyzedCases
Other,50PercecntRelapsedTissues
Other,510YearsAfterSurgery
Other,51Days
Other,535941Survivors
Other,54BreastCancerPatients
Other,56Patients
Other,576Percecnt
Other,57PercecntOfPatients
Other,5CmLess
Other,5-Fluorouraci
Other,5-khzFrequencies
Other,5Percecnt
Other,5T-mds/mpn
Other,5-yearResultsOfPhase3Isg23-01Trial
Other,5Μl
Other,606Percecnt
Other,6084Years
Other,62Years
Other,643Percecnt
Other,65Months
Other,65Ng/ml
Other,65Ng/mlForProgranulinFor-1
Other,65-year-oldFemale
Other,68Percecnt
Other,-69PercecntTo+239Percecnt
Other,6Months
Other,6Years
Other,7051UnselectedBreastCancerPatientsOfJapaneseAncestry
Other,713Percecnt
Other,713PercecntWithHighHeterogeneity
Other,72Months
Other,731Percecnt
Other,73-yearOldWomanPresentingWithLeftBreastLumpClinicallyIndeterminate
Other,768PercecntSamplesWithOverexpressionIn76Cases
Other,773Percecnt
Other,77Patients
Other,7Percecnt
Other,7PercecntForCdx2
Other,8155Patients
Other,83Percecnt
Other,845Percecnt
Other,84Patients
Other,876Percecnt
Other,876PercecntRespectively
Other,89FfdmCases
Other,89Participants
Other,89Years
Other,90Percecnt
Other,90PercecntOfPatients
Other,90PercecntOfPatientsWithRecurrence
Other,91Percecnt
Other,91PercecntInPatientsWithBreastTumors
Other,93Percecnt
Other,952PercecntOfthePostmenopausalWomen
Other,95PercecntCi646-779Percecnt
Other,95PercecntConfidenceIntervals
Other,992Percecnt
Other,992PercecntOfCases
Other,99Percecnt
Other,99PercecntOfCases
Other,9h-pyridoPyrrolizin-9-one
Other,a549Cells
Other,abbreviatedMriProtocols
Other,aberrances
Other,aberrantExpression
Other,aberrantExpressionOfBIn21PercecntRespectively
Other,aberrantlyExpressed
Other,aberrantMethylationDetection
Other,aberrations
Other,able
Other,abnormalUterineBleeding
Other,about1Year
Other,about30Percecnt
Other,aboveConditions
Other,abstractDataOnTheirClinicalCharacteristics
Other,abundantlyPresent
Other,acceleratedPartialBreastIrradiation
Other,acceptableSafetyMargins
Other,access
Other,accessToEarlyDiagnosis
Other,accessToReceptorAnalysesInCytosolAtDiagnosis
Other,accomplished
Other,accurateDiagnosisOfBreastCancerSubtypes
Other,accurateMethod
Other,achieved
Other,achievedForHer2Status
Other,acid
Other,acquisition
Other,activatedComplex
Other,active
Other,actSynergisticallyWithPaclitaxel
Other,actualIncidence
Other,Acupuncture
Other,added
Other,addition
Other,additionalAnalyses
Other,additionalAnti-her2Therapy
Other,additionalIndicator
Other,additionalInformation
Other,additionallyCorrelated
Other,additionallyRevealed
Other,add-onToConventionalUltrasoundEquipmentApplicable
Other,adenocarcinomaFeatures
Other,adenosine-inducedScEnrichment
Other,adherence
Other,adherenceToEhtAmongBreastCancerPatients
Other,adherenceToRecommendationWith95PercecntConfidenceIntervals
Other,adipocytes
Other,adjustedProportion
Other,adjustingForPotentiallyConfoundingFactors
Other,adjuvantAnastrozole
Other,adjuvantRadiotherapy
Other,administered
Other,administrationOfNeoadjuvant
Other,adPatients
Other,adult1-yearCancerSurvivors
Other,adulthood
Other,adultPatientsDiagnosed
Other,adults
Other,advance
Other,advancedAnalysis
Other,advancedBreastCancerBearingMutations
Other,advancedBreastCancerBearingMutationsInGenesInvolvedInPi3k/ark/mtorSignalingPathway
Other,advancedBreastCancerTreatment
Other,advancedComputationalSystems
Other,advancedDiagnosticImaging
Other,advancedStage
Other,advancedTechnologies
Other,advances
Other,advancesInBreastCancerDiagnosis
Other,advantage
Other,advantageOfHigh-throughputLuminexTechnique
Other,advantages
Other,adverseEffects
Other,adverseEffectsOfMtorInhibitors
Other,adverseEventsExceptDegreeI-iiBleeding
Other,affected
Other,age-basedScreeningPrograms
Other,age-matchedSystematicRandom-samplingMethod
Other,agents
Other,ages
Other,aggressive
Other,aggressiveManagement
Other,ai-associatedSevereTendinopathy
Other,ai-associatedTendinopathy
Other,aiDiscontinuation
Other,aim
Other,aimed
Other,Aims
Other,alarm
Other,alcoholConsumption
Other,alexnetModels
Other,algorithm
Other,all
Other,allBreastCancerPatients
Other,allCloselyAssociatedWithPttTherapeuticEfficacy
Other,allow
Other,alongsideRoutineMethodEmployedOnTexture
Other,alreadyWell-established
Other,alsoAssessed
Other,alsoAssessedByQrt-pcr
Other,alsoAssociated
Other,alsoObserved
Other,alsoShaped
Other,alsoSignificantlyLower
Other,alsoUsed
Other,alteredInHumanBreastCarcinoma
Other,alternative
Other,alternativeContrast-enhancedScreeningTools
Other,alternativeOption
Other,alternativeToFrozenSections
Other,alveolar-interstitialLesions
Other,amino-terminalFragment
Other,amongYoungerPeopleCommon
Other,amplifications
Other,an
Other,analysed
Other,analyses
Other,analysis
Other,analysisInvestigate
Other,analysisOfLncrnaExpressionProfiles
Other,analyzed
Other,andfemales
Other,Anemia
Other,Angiogenesis
Other,annexinV-fluoresceinIsothiocyanate/propidiumIodide
Other,annualMammographyAssociatedWithEchography
Other,anotherOfSeveralIndividualsInOneFamilyAffectedByCs
Other,anthracyclineChemotherapyAgents
Other,Anthracyclines
Other,anti-apoptoticEffectsOfEstradiol
Other,antibodies
Other,antibody-anchoredMagneticBeads
Other,antibody-basedStrategy
Other,antibodyDrugConjugates
Other,antibodyHerceptin
Other,anticipated
Other,anticipatedOutcome
Other,antigenIdentification
Other,anti-her2Therapies
Other,anti-her2Therapy
Other,anti-oncogenicRegulationOfMir-34s
Other,anti-ronMonoclonalAntibodyZt/g4-drugMonomethylAuristatinEConjugate
Other,APBI
Other,apoptosis
Other,Applications
Other,applicationsOfRadiomics
Other,applied
Other,appliedTo70PatientsWithUnilateralRl
Other,approach
Other,approaches
Other,appropriateAllocationOfResearchFunding
Other,appropriateDiagnosisOfBreastCancer
Other,appropriateIntegrationOfPreprocessing
Other,appropriateInterpretation
Other,appropriateQuality
Other,approved
Other,approximated
Other,approximately75PercecntOfBreastCancers
Other,archivedFormalin-fixedParaffin-embeddedTissue
Other,area
Other,areaOfResidence
Other,Areas
Other,areInvestigated
Other,areUsed
Other,arms
Other,article
Other,AS
Other,asianCountries
Other,asianPopulation
Other,aspect
Other,aspects
Other,aspirinTherapy
Other,aspirinUse
Other,asResultAreUsed
Other,assessed
Other,assessedinclusionCriteriaForEnrolment
Other,assessedPreoperatively
Other,assessments
Other,ASSIA
Other,associated
Other,associatedWithBreastCancerRisk
Other,associatedWithPfsAlthoughAtExtent
Other,association
Other,associationBetweenRace/colorInWomenWithBreastCancer
Other,associationOfPcdh10Methylation
Other,associationOfToll-likeReceptor6WithBreastCancerInSaudiArabianWomen
Other,associations
Other,associationsBetweenAspectsOfDiet
Other,associationsOfFactorsWithLocoregionalAtDiagnosis
Other,associationsWithDiseasesLikeTypeI
Other,associationWithImagingOfIgm
Other,asymptomaticWomen
Other,asymptoticPropertiesOfEstimatesCalculatedFrom
Other,attention
Other,attentionToSpecialGroups
Other,AUC
Other,australianSynchrotron
Other,automatedAnalysisOfClinicallyRelevantHistopathologicFeature
Other,automaticIntraoperativeIdentificationOfBreastCancerMargins
Other,autonomyOfPatients
Other,autopsyStudies
Other,autosomal-dominantlyInheritedCancerSyndromeAssociatedWithRiskCausedByHeterozygousCdh1GermlineMutations
Other,available
Other,availableContrastAgents
Other,avoidance
Other,axillary
Other,axillaryDissection
Other,axillarySurgery
Other,backgroundTrastuzumab
Other,back-splicingMechanism
Other,balb/cNudeMiceBearing
Other,balfOfNsclcPatients
Other,barcodeMode
Other,Barshi
Other,based
Other,bayesianNetworkMeta-analysis
Other,Belgium
Other,benign
Other,benignBreastLesions
Other,bestAvailableEvidence
Other,beta-SDG
Other,beta-Sitosterol-d-glucoside
Other,betterUnderstanding
Other,bevacizumab-relatedCardiotoxicity
Other,bevelledEdges
Other,bilateral
Other,bilateralBreastLumps
Other,bilateralInvolvement
Other,binding
Other,bindingSites
Other,bindingToBreastCancerCellsInVitro
Other,bioactivity
Other,biocompatiblePfh-ptx@plga
Other,bioimpedanceAnalysis
Other,bioinformaticAnalysis
Other,biologicalHeterogeneity
Other,biologicallyDifferentDisease
Other,biologicallyDifferentDiseaseInWomen
Other,biologicalSubtypes
Other,biomarker
Other,biomarkers
Other,biopsy
Other,bivariateAssociations
Other,bl1-subtype
Other,bl1-subtypeTriple-negativeBreastCancer
Other,blackWomen
Other,bleedingRates
Other,bleedingRisk
Other,blood
Other,bloodSamples
Other,bloodVesselsFormation
Other,bLymphocyteChemoattractant
Other,BMI
Other,body
Other,bone-modulatingAgents
Other,borders
Other,bortezomib-inducedColdAllodynia
Other,brain
Other,brainMetastases
Other,brainMetastasisFromPapillaryThyroidCarcinoma
Other,brca1Levels
Other,brca1Wild-typeCells
Other,brca1Wild-typeTripleNegativeBreastCancer
Other,brca-associatedCancers
Other,brcanessPhenotype
Other,brcanessPhenotypeInBrca1Wild-typeCells
Other,BRCAs
Other,brcc3Expression
Other,brcc3ExpressionLevels
Other,brd4Inhibition
Other,brd4PharmacologicalInhibition
Other,brd4Regulation
Other,Breast
Other,breastBiopsies
Other,breastCancerAged
Other,breastCancerBrainMetastases
Other,breastCancerCare
Other,breastCancerCases
Other,breastCancerCells
Other,breastCancerClassification
Other,breastCancerConfinedWithinMammaryDuctsSurrounded
Other,breastCancerDetectionMethod
Other,breastCancerGenes
Other,breastCancerGrading
Other,breastCancerImagingSetting
Other,breastCancerInAdultsInChildren
Other,breastCancerIncidence
Other,breastCancerMcf-7
Other,breastCancerMetastasis
Other,breastCancerPatients
Other,breastCancerPatientsSerum
Other,breastCancerPatientsWithParticularReferenceToOverallSurvivalAndrecurrenceFreeSurvivalAmongBreastCancerPatients
Other,breastCancerRisk
Other,breastCancerScreening
Other,breastCancerScreeningProgramme
Other,breastCancer-specific10-yearSurvival
Other,breastCancerStudies
Other,breastCancerSubtypesa
Other,breastCancerTherapy
Other,breastCancerTissue
Other,breastCancerTissueMicroarrayWithAccessToReceptorAnalyses
Other,breastCancerTissues
Other,breastCancerTreatment
Other,breastCancerYoungerThan45Years
Other,breastConservation
Other,breastExamination
Other,breastImagingModality
Other,breastReconstruction
Other,breastScreening
Other,breastSurgery
Other,breastSurveillance
Other,breastSurvival
Other,breastTumorigenesis
Other,breastUltrasound
Other,broadcasted
Other,broadUseToPatients
Other,bt549Cells
Other,burdenOfCervicalCancer
Other,byDevelopmentOfHybridomaTechnologyHaveProducedInManyLaboratories
Other,byMultivariateAnalysisSignificantIndependentPrognosticFactorOfOs
Other,C
Other,c.
Other,C1
Other,c1711
Other,ca15-3ByCmia
Other,ca15-3Detection
Other,caDetection
Other,calculated
Other,caloricRestriction
Other,canBenign
Other,canCategorized
Other,canCategorizedIntoSubtypesOfLuminalA
Other,cancerAssociatedFibroblasts
Other,cancerCare
Other,cancerCareNetwork
Other,cancerCareSystems
Other,cancerCells
Other,cancerClassification
Other,cancerCounseling
Other,cancerDeathAmongWomenWorldwide
Other,cancerDiagnosis
Other,cancerFibroblasts
Other,cancerManagement
Other,cancerMolecularDiagnosis
Other,cancerPatients
Other,cancerProgression
Other,cancer-relatedDeathInChineseWomen
Other,cancer-relatedDeathsAmongWomen
Other,cancerResearch
Other,cancerRiskPerception
Other,cancerSignaling
Other,cancerStaging
Other,cancerSurvival
Other,cancerSurvivors
Other,cancerSusceptibilityGenes
Other,cancerTherapy
Other,cancerTreatment
Other,cancerType
Other,canClassified
Other,canClassifiedAsSoluble-proteinBasedImmunocytochemical
Other,canDetected
Other,canDetectedInBodyFluidsIncludingSerum/plasmaSamples
Other,canDetectedInManyBodyFluidsIncludingSerum/plasmaSamples
Other,canDiagnosed
Other,canDifficult
Other,canEasilyExtended
Other,canExtended
Other,canHeavilyInfluenced
Other,canIncluded
Other,canIncludedInDifferentialDiagnosisOfMasses
Other,canines
Other,canineTumours
Other,canOnlyDiagnosedOnPresentationOfSymptoms
Other,canStressful
Other,canStressfulToPatient
Other,canUsed
Other,capabilities
Other,capacities
Other,capecitabineRegimenAsThird-lineTreatmentForAdvancedTriple-negativeBreastCancer
Other,carbohydrateRestriction
Other,carboxyl-modifiedPegylatedPoly
Other,cardiotoxicRisk
Other,care
Other,careProvider
Other,Cases
Other,causal
Other,causes
Other,CA-VTE
Other,CEDM
Other,Cell
Other,cellDeath
Other,Cells
Other,cent
Other,centralImplantedVenousAccessDevices
Other,centralRoleInBreastCancerResearch
Other,certainCancers
Other,cervical
Other,CESM
Other,CGI
Other,challenge
Other,challenges
Other,challenging
Other,challengingProblem
Other,Change
Other,changes
Other,chapter
Other,characteristics
Other,characteristicsOfHighDimensions
Other,characterization
Other,characterized
Other,charts
Other,chemotherapy
Other,chemotherapyGroups
Other,chemotherapyHormonalTreatment
Other,chemotherapyRegimens
Other,Chi
Other,childbearingReasonsIncluding
Other,childHealth
Other,China
Other,chinesePublic
Other,chlorambucilPlatinum
Other,chosen
Other,CIAPIN1
Other,Circ-EFCAB2
Other,circRNAs
Other,circularRnas
Other,circulatingBiomarkers
Other,circulatingSolubleRankl
Other,circumferentialNarrowingOfCaecum
Other,CK
Other,ck5/6
Other,claimsDatabase
Other,clarify
Other,class
Other,classic
Other,classificationOfMammograms
Other,classified
Other,classifiers
Other,CLB-Pt-CLB
Other,clb-pt-clbProdrug
Other,clinicalBreastExamination
Other,clinicalBreastExaminationCoupledAsPrimaryTool
Other,clinicalCare
Other,clinicalCharacteristics
Other,clinicalCharacteristicsOfCareOfBreastCancerPatients
Other,clinicalDepression
Other,clinicalDiagnosticPathways
Other,clinicalFeatures
Other,clinicalOutcomesDiffer
Other,clinicalPicture
Other,clinicalPractice
Other,clinicalRecords
Other,clinicalSetting
Other,clinicalSettingOfPreviouslyVagueDiagnosisInImaging
Other,clinicalTrials
Other,clinicalVariablesAmongDifferentGroups
Other,clinicalVisits
Other,clinicians
Other,clinico-epidemiologicalFeaturesOfBreastCancer
Other,clinico-pathologicalFeaturesOfMetastases
Other,clinicopathologicalFeaturesOfT-mnPatients
Other,clinico-pathologicalRiskFactors
Other,clinicopathologicalSignificance
Other,clinocopathologicOfPi3k/akt/ptenPathwayInMoroccanTripleNegativeBreastCancerPatients
Other,closelyAssociated
Other,cm
Other,CMIA
Other,CNN
Other,cnvData
Other,CNVs
Other,cnvsOfDifferentCancers
Other,coding
Other,Co-existence
Other,cohort
Other,collected
Other,collectedFromElectronicHealthRecord
Other,collectedSignatures
Other,collection
Other,colon
Other,colonyFormation
Other,colorectalTissue
Other,combination
Other,combinationsOfInductionInBrca1Wild-typeTripleNegativeBreastCancer
Other,combinedAnalysis
Other,common
Other,commonAdultCancers
Other,commonCancer
Other,commonCancerTypes
Other,commonComplaint
Other,commonFeature
Other,commonFinding
Other,commonMalignantDisease
Other,commonMedications
Other,commonOnes
Other,commonPlatformForStakeholdersIncludingPolicymakers
Other,compactSynchrotronSources
Other,comparable
Other,compared
Other,comparedBetween2GroupstheApatinib
Other,comparedToThoseWithPregestationalBreastCancer
Other,comparingWithCurrentStandardMethodOfSubjectiveVisualEstimation
Other,comparison
Other,comparisonCohort
Other,comparisonOfPredictedIncidenceOfBreastCancerWithActualIncidenceInPopulation-basedStudies
Other,Comparisons
Other,comparisons10-yearSurvival
Other,comparisonToCa15-3
Other,complaint
Other,complementaryApproaches
Other,completionOfReproductivePlans
Other,complex
Other,complexConsulting
Other,complexDueToPotentialFoetalRisksInSettingOfMaternalTreatment
Other,complexKaryotypes
Other,complexSemisolidMasses
Other,complexSemisolidMassesWithVaryingAmountsOfSolidComponents
Other,complexTreatmentAlgorithms
Other,component
Other,components
Other,compounds
Other,compounds19a
Other,comprehensiveResearchData
Other,comprehensiveSearch
Other,computedTomography
Other,computedTomographyOfBrain
Other,concentrations
Other,concentrationsOfVegf-aInComparisonToCa15-3InBreastCancer
Other,concerned
Other,concernForExistenceOfCancerCellsInGrafts
Other,concerns
Other,conclusionsInPractice-basedSampleOfCa-vtePatientsAssociatedWithSimilarBleedingRisksToWarfarin
Other,conclusionsWomen
Other,concomitantlyShouldAnalyzed
Other,concurrentNeuroprotectiveDrugTherapy
Other,conditions
Other,conducted
Other,confidentDiagnoses
Other,confirmed
Other,confounders
Other,conjugatedEquineEstrogen
Other,connected
Other,connection
Other,consensus-based
Other,consequentlyHaveDeveloped
Other,consequentlyPredicted
Other,conservativeTreatment
Other,considerableNumber
Other,considerations
Other,considered
Other,consistent
Other,consistentMass-spectralData
Other,consolidativeRadiotherapy
Other,consultations
Other,context
Other,contexts
Other,continuousDynamicCyclesOfFission
Other,continuousPattern
Other,continuousRisk
Other,contraceptiveUse
Other,contralateralBreast
Other,contrast
Other,contrastAfterInjection
Other,contrastAgents
Other,contrast-enhancedSpectralMammography
Other,contrastEnhancement
Other,contrastRatio
Other,contribution
Other,controlled
Other,controls
Other,controversial
Other,conventionalMagneticResonanceImaging
Other,conventionalX-rayMammography
Other,convolutionalNeuralNetworks
Other,cornerstone
Other,correctDiagnosis
Other,correctionMethod
Other,correlated
Other,correlation
Other,correlationCoefficient
Other,correlationCoefficientOnMetabricTrainingSet
Other,correlativeEntities
Other,correspondingCohort
Other,cosmesis
Other,costData
Other,costOfMriExamination
Other,costs
Other,couldConsidered
Other,couldDetected
Other,couldDetectedByMammographyBySelf-detection
Other,couldDetectedEarly
Other,couldDeveloped
Other,couldEmployed
Other,couldIndependentPrognosticBiomarkerForMPatients'Outcomes
Other,couldPotentialBiomarker
Other,couldSutegorized
Other,couldSutegorizedIntoT2aWithCutoffValueOf3Cm
Other,counseling
Other,countries
Other,country
Other,covariates
Other,coverageRates
Other,coxModels
Other,cpgIslands
Other,crcPatients
Other,CRD42016048917
Other,created
Other,critical
Other,criticalImplicationsForTherapeuticDecision-makingInUrothelialCancer
Other,criticalRole
Other,criticalRoles
Other,cross-linked
Other,cross-sectionalCategories
Other,cross-sectionalStudies
Other,cross-validation
Other,crucial
Other,crucialRole
Other,cruciferousVegetables
Other,Cryopreservation
Other,ctcCounts
Other,CTCs
Other,CTIBL
Other,cTn
Other,ctnLevels
Other,cure
Other,currentAnalysis
Other,currentBio-sensingTechniques
Other,currentCancerResearch
Other,currentEvidenceOnEfficacyOfHer2-targetedTherapiesInOlderAdultsWith
Other,currentlyInsufficient
Other,currentlyUnclear
Other,currentResults
Other,currentTherapiesAvailable
Other,currentUtilizedHistopathologicBiomarkers
Other,cutaneousMetastasis
Other,cutoff
Other,cutoffValue
Other,cutoffValues
Other,cxcSubtypeOfChemokineSuperfamily
Other,cylindricalGeometries
Other,cystic
Other,cytogeneticAnalysis
Other,cytotoxic
Other,cytotoxicActivitiesOnMcf7
Other,danger
Other,Data
Other,dataOfN=
Other,dataOn108Pb-dllPatientsFrom21ChineseMedicalCenters
Other,datasets
Other,DAU
Other,dcisDiagnosis
Other,DCR
Other,DDTs
Other,debated
Other,decades
Other,decision
Other,decision-making
Other,decreased
Other,decreasedExpression
Other,decreasedGrowth
Other,decreasedRisk
Other,decreasedRiskOfBreastCancerInFemaleAdPatients
Other,decreases
Other,decreasesInMortalityRates
Other,deep-CNN
Other,deepLearning
Other,defined
Other,definedSubtype
Other,definiteDiagnosisParticularlyInSmallBiopsies
Other,definition
Other,delay
Other,delaysinTreatment
Other,Demographics
Other,demonstrate
Other,denosumabInjection
Other,denseBreasts
Other,denseBreastTissue
Other,dependent
Other,dependentOnRigorousPathologicEvaluationOnAdministrationOfTreatmentDictatedByTumorBiology
Other,depicted
Other,Depletion
Other,deregulatedMirnas
Other,described
Other,description
Other,descriptive
Other,descriptive-analyticCross-sectionalType160FemalePatientsWasselected
Other,designed
Other,designedByDivisionForBreastCancerOfKoreanRadiationOncologyGroup
Other,desirable
Other,detailedAnalysis
Other,detailedRoles
Other,detected
Other,detectedThroughScreeningThroughSigns
Other,detection
Other,detectionofBreastCancer
Other,detectionOfBreastCancerInWomen
Other,detectionOfCancer
Other,detectionOfMicrocalcificationInMammograms
Other,detectionRate
Other,determinantGenes
Other,determinantGenesRelatedToBreastCancerFromInitialGeneExpressionData
Other,determinantsOfCancer
Other,determinationOfUnderlyingBiologyWithinTumors
Other,determine
Other,determined
Other,devastatingDiagnosis
Other,developed
Other,development
Other,developmentOfBrainCancers
Other,developmentOfBreastCancer
Other,developmentOfClinicalDecisionSupportSystemsForBreastCancerDiagnosis
Other,developmentOfGraphicallyTailoredScreeningTool
Other,developmentOfManyMetabolicDisorders
Other,developmentOfMetabolicDisorders
Other,developmentOfPolicies
Other,developmentOfSubsequentLung/bronchusCancer
Other,diagnosed
Other,diagnoses
Other,diagnosis
Other,diagnosisInMajorityOfInconclusiveCases
Other,diagnosisOfAcuteCoronarySyndromes
Other,diagnosisOfBreastCancer
Other,diagnosisOfCancer
Other,diagnosisOfEstrogenReceptor
Other,diagnosisOfPatientsWithBreastCancer
Other,diagnosisSystem
Other,diagnosticChallenge
Other,diagnosticEvaluation
Other,diagnosticPfBiomarkers
Other,diagnostics
Other,dictionaryLearning
Other,diet
Other,differences
Other,different
Other,differentBreastCancerMolecularSubtypes
Other,differentClinicalOutcomes
Other,differentGeneticProfile
Other,differentHistologicalAspects
Other,differentialDiagnosis
Other,differentialDiagnosisInPatientsWithHistoryOfBreastSurgery
Other,differentialExpression
Other,differentiallyExpressedCircularRnasInNeurologicalDisorders
Other,differentiallyExpressedInBreastCancerCells
Other,differentiallyModulated
Other,Differentiation
Other,differentiationBetweenBreastCancerInVariousSubtypesOfBreastCancer
Other,differentLevelsOfCk19
Other,differentLong-termSurvival
Other,differentmethodsOfSelf-treatment
Other,differentOss
Other,differentPatientRaces
Other,differentPhenotypes
Other,differentPhotosensitizerForPhotodynamicTherapy
Other,differentPrognosis
Other,differentProtocols
Other,differentStudies
Other,differentSubtype
Other,differentTreatmentModalities
Other,diffuse
Other,diffuseGastricCancerPresentedWithClp
Other,digitalBreastTomosynthesis
Other,directEffects
Other,directlyAffectedByOverexpressionDownRegulationOfManyMirnas
Other,directRelationship
Other,directTargetGene
Other,disadvantages
Other,discovered
Other,discrete-timePartiallyObservableMarkovDecisionProcess
Other,discussed
Other,Disease
Other,diseaseDefinedByTumor
Other,diseaseDiagnosis
Other,diseases
Other,disrupted
Other,dissection
Other,dissectionOfLymphNodes
Other,disseminatedDisease
Other,distinction
Other,distinctiveGeneticModifications
Other,distributions
Other,divergences
Other,diverse
Other,diverseBiologicalProcesses
Other,diverseMalignantTumors
Other,divided
Other,DOACs
Other,documented
Other,dominantArms
Other,dopamineAgonist
Other,dopamineAgonists
Other,dose
Other,doseConcerns
Other,dose-dependentReduction
Other,dose-dependentReductionInBrca1Levels
Other,doses
Other,double-maintenanceTherapy
Other,doublingTimeOfOccult
Other,downregulated
Other,downregulatedIn
Other,Downregulation
Other,DPV
Other,dramaticallyIncreasedAmount
Other,drawbacks
Other,driven
Other,drugBinding
Other,drugDecay
Other,drugExtravasation
Other,drugTherapy
Other,dryness
Other,dual-energyAcquisition
Other,dual-luciferaseReporterAssays
Other,dualRole
Other,dualRoleOfL-3InBl1-subtypeTriple-negativeBreastCancer
Other,ductalCarcinoma
Other,due
Other,dynamicContrast
Other,dysregulation
Other,each
Other,earlierAges
Other,earlyBiomarkersOfBreastCancerRisk
Other,earlyBreastCancer
Other,earlyBreastCancerDetectionSystems
Other,earlyBreastCancerDiagnosisOfBreastCancerRisk
Other,earlyCancerDiagnosis
Other,earlyDetectionOfSeveralCancerTypes
Other,earlyDiagnosis
Other,earlyDiagnosisOfCancerPatients
Other,earlyStage
Other,earlyStageDiagnosisOfTumors
Other,easternAsianMusculoskeletalOncologyGroup
Other,edition
Other,effective
Other,effectiveDiagnosisOfBreastCancer
Other,effectiveness
Other,effectivenessOfDifferentNpatsOnQolInPatientsWithBreastCancer
Other,effects
Other,effectsOfPcosOnRisksOfGynecologicCancer
Other,effectsOfTreatment
Other,efficacy
Other,efficientlyCross-linked
Other,efficientlySynthesized
Other,efficientSignaturesForClinicalDiagnosis
Other,Efforts
Other,eighthEdition
Other,elderlyPatientWithRelapsedHer2
Other,electricalDouble-layerCapacitors
Other,elevatedMitochondrialFission
Other,elevenPatients
Other,ELISA
Other,elusive
Other,elusiveToTargetedTherapies-theTriple-negativeBreastCancer
Other,emergingPublicHealthProblemInLowCountries
Other,emergingTechnology
Other,empiricalTreatmentsBasedOnClinical-pathologicalCharacteristicsToUseOfTargetedApproaches
Other,employed
Other,EMT
Other,encapsulatedSuperparamagneticIronOxideNanoparticles
Other,enforcedExpression
Other,enhanced
Other,enhancedPossibility
Other,enrolled
Other,entities
Other,environmentalFactors
Other,epidemiologicalFeatures
Other,Epidemiology
Other,epigeneticAberrations
Other,epigeneticChanges
Other,eralphaSignalling
Other,eralphaTranscription
Other,erCscs
Other,erEvaluation
Other,ERN
Other,ernGenturis
Other,especiallyFrequentLateRelapsesInCnsBreast
Other,especiallyPost-neoadjuvantTreatment
Other,especiallyPromising
Other,essential
Other,essentialRole
Other,essentialsBleedingRisk
Other,essentialsRisk
Other,established
Other,establishedOncogene
Other,estimated
Other,estimates
Other,estrogen-aloneArmOfWhi
Other,estrogenReceptor
Other,estrogenReceptorBeta
Other,etiologyOfManyDiseases
Other,eukaryoticTranscriptome
Other,Europe
Other,europeanCountries
Other,evaluated
Other,evaluatedInVivo
Other,evaluation
Other,evenAdjustedForKnownPrognosticFactors
Other,evenNeeded
Other,evenSeveralChemotherapySessions
Other,evenSubgroupOfPatientsTreatedWithRituximab
Other,eventHybridizationOfMirna-21Biomarker
Other,events
Other,everolimus-exemestaneCombination
Other,evidence
Other,evidence-basedDecision-makingForPopulation
Other,evidence-basedRecommendations
Other,evidencedByIncreaseInContrastAfterInjection
Other,evidenceForbenefits
Other,evidenceOffer
Other,evolutionaryConservedCircularRnas
Other,evolve
Other,evolveTowardLessSurgery
Other,exactTest
Other,examination
Other,examinations
Other,examined
Other,example
Other,exceedinglyRare
Other,excision/lumpectomy
Other,existence
Other,exon32OfMammalianTargetOfRapamycin
Other,expected
Other,expectedInverseCorrelation
Other,expectedInverseCorrelationOfSerumDdtsWithBmi
Other,experiences
Other,experts
Other,explored
Other,exposed
Other,expressed
Other,expressedCircularRnas
Other,expressedSeparately
Other,expression
Other,expressionInBreastCancer
Other,expressionLevels
Other,expressionLevelsOfProteinsAssociatedWithEpithelial-mesenchymalTransition
Other,expressionOf6CirculatingMirnasInOperablePatients
Other,expressionOfChemokineReceptor-4
Other,expressionOfMir-511InBreastCancer
Other,expressionOfOtherBiomarkers
Other,expressions
Other,extendedAdjuvantTreatment
Other,extensiveAttentionOfResearchers
Other,extensiveExploration
Other,extensiveMolecular
Other,extremeLearningMachineClassification
Other,extremelyRare
Other,factor
Other,factor-1Scores
Other,factorAnalysis
Other,factors
Other,factorsRelatedToPresenceOfMetastaticDiseaseAtDiagnosis
Other,failure
Other,falsePositives
Other,familialCancerClustering
Other,familialCancerClusteringInPatientsWithProlactinoma
Other,family
Other,familyHistory
Other,familyHistoryOfDisease
Other,familyMember
Other,familyMemberAffectedWithCancer
Other,familyMembers
Other,familyOfNoncodingRnas
Other,familySupport
Other,faSignalingNetwork
Other,fastingBlood
Other,feasibilityStudies
Other,feasible
Other,feature
Other,featured
Other,featureFactorsOfPrss
Other,featureMining
Other,featureMiningFromRois
Other,features
Other,featureSelection
Other,featureSelectionMethod
Other,featureSubset
Other,featureSubsets
Other,february2012InNargisDuttMemorialCancerHospital
Other,female
Other,femaleBreastCancerMortality
Other,femaleNudeMice
Other,femalePatients
Other,femalePatientsWithAd
Other,femaleSibling
Other,female-specific
Other,fewerInstancesOfSpreadToLungs
Other,fewLmics
Other,fewPercentOfWomen
Other,fewStudies
Other,FFDM
Other,fibroblasts
Other,fibroblastsAdjacent
Other,figures
Other,filipinoWomen
Other,finding
Other,findings
Other,findingsFromStudies
Other,firmlyPlaceWithRecentTrendsTowardDecreasedRatesOfRe-excision
Other,first-lineTreatment
Other,fisherAnalysis
Other,fisherDiscriminantAnalysis
Other,fission
Other,five
Other,fiveDoses
Other,fiveDosesOfAdjuvantTranstuzumab
Other,fiveGroups
Other,fiveMutationCarriers
Other,five-yearLocalRecurrenceRates
Other,five-yearMetastasis-free
Other,five-yearOsRate
Other,fiveYearRfsrate
Other,fiveYearsPosttreatment
Other,flankingCgi
Other,flowCytometry
Other,flowRate
Other,fluorescenceImagingExVivo
Other,focal
Other,focalNeurologicDeficit
Other,focus
Other,followed
Other,following
Other,Follow-up
Other,forefront
Other,forefrontOfResearch
Other,formationOfCircularizedRna
Other,formed
Other,formedByCo-encapsulationOfNear-infraredFluorophoreInPegylatedMicelles
Other,formulation
Other,formulationOfEffectiveManagementPlanForAt-riskWomen
Other,forRace/colorVariableEstimatedWithAdjustmentForStatus
Other,forThoseWithNormalLvef93Percecnt
Other,forwardProblem
Other,forWomenWithBreastCancerMayMoreFeasible
Other,found
Other,foundInPcosCohortThanInComparisonCohort
Other,fourGroups
Other,fourSelectedPopulation-basedCancerRegistries
Other,fourTypesOfBreastCancer
Other,foxc1Function
Other,foxc1-knockdownBt549Cells
Other,fpReduction
Other,fpReductionTechnique
Other,FPs
Other,frequency
Other,frequent
Other,frequentCancer
Other,frequentInformationalNeeds
Other,frequentLateRelapses
Other,frequentlyDetected
Other,from33ObservationalStudiesExposedToTrastuzumabTherapy
Other,function
Other,functionalAssessments
Other,functionalizationStepsForRapidDetection
Other,functions
Other,fundamental
Other,fundamentalComponents
Other,furtherAdvancements
Other,furtherDevelopment
Other,furtherFound
Other,furtherImaging
Other,furthermoreAssociated
Other,furthermoreEnhanced
Other,furthermoreHaveSuggestedAsPotentialCirculatingNoninvasiveBiomarkersForEarlyDetectionOfGastricCancers
Other,furthermoreRestricted
Other,furtherResearch
Other,furtherStudies
Other,furtherUnderstanding
Other,fused
Other,fusionProteinsWithHaloTag
Other,future
Other,futureDirections
Other,fxyd3Amplification
Other,G
Other,gaslessRobot-assistedNipple-sparingMastectomy
Other,gender
Other,geneExpressionData
Other,geneExpressionUpregulationInBreastCancer
Other,general
Other,generalBreastCancerPopulation
Other,generalHealth
Other,generallyReserved
Other,generalPopulation
Other,generalRadiologistAboutSystemicDiseases
Other,genes
Other,genesCodingForTumorSuppressorProteins
Other,genesInvolved
Other,Genetic
Other,geneticChanges
Other,geneticMalignancyPredispositionSyndrome
Other,geneticPredispositionForCancer
Other,genitalTract
Other,genitalTract'sMetastases
Other,geometries
Other,given
Other,givenRecentConcernsAboutGadolinium-basedContrastAgentsAreAlsoInvestigatedForBreastCancerDiagnosis
Other,globalHealth
Other,glut1Expression
Other,good
Other,goodCorrelationBetweenErAnalysedWithCytAtDiagnosisAnalysedWithIhcInArchivedFfpeTissueFromSameTumour
Other,goodTolerabilitytheApatinib
Other,grafts
Other,greatBenefitsAgainstBreastCancer
Other,greater
Other,greaterthan1500Pg/ml
Other,greaterthanorequalto10PercecntReductionInLvef
Other,greaterthanorequalto1Lineage
Other,greaterthanorequaltoReduction
Other,greatestDivergences
Other,greatestImportance
Other,greatPotentialInDiagnosisTherapyOfCancers
Other,greatProgress
Other,greatPromise
Other,group-basedTrajectoryModelling
Other,groups
Other,growing
Other,growingProblem
Other,growth
Other,growthImplicatedInTumorigenesis
Other,growthPotential
Other,gsAlgorithm
Other,GTPase
Other,gtpaseInBreastCancerCells
Other,guidedImagery
Other,guidePatients
Other,gynaecologicalMetastases
Other,h&eStaining
Other,HADS
Other,hampered
Other,handicap
Other,harmfulorHarmlessTissues
Other,harmToHealthAmongRuralWomenWithIncrementalCost-effectivenessRatio
Other,hasAchieved
Other,hasAlreadyAssociatedWithDifferentCancersNon-hodgkin'sLymphoma
Other,hasApplied
Other,hasAssociated
Other,hasAssociatedWithPoorCancerScreeningUptake
Other,hasDescribedInFewHdgcFamilies
Other,hasDeveloped
Other,hasEstablished
Other,hasFocused
Other,hasFocusedOnTumourCellsPrimarily
Other,hasFound
Other,hasInconsistent
Other,hasIncorporated
Other,hasIncorporatedIntoClinicalPracticeForOver100YearsAtLowCost
Other,hasMade
Other,hasMadeInMolecularSubtypingOfBreastCancer
Other,has-miR-3158-3p
Other,hasObserved
Other,hasProposed
Other,hasProven
Other,hasPut
Other,hasPutOnIntrinsicSubtypingBasedInPresenceOfClassicalImmunohistochemistry
Other,hasRecentlyDeveloped
Other,hasRecentlyProposedAsCrucialRegulator
Other,hasReduced
Other,hasReported
Other,hasSuggested
Other,hasUsed
Other,hasUsedInLeukemia
Other,hasValidatedDatabase
Other,hasWidelyUsed
Other,haveAllProposedAmongPotentialPathways
Other,haveAssociated
Other,haveBackbone
Other,haveBackboneOfSuchEnormousStridesOfAu
Other,haveCenterstage
Other,haveClarified
Other,haveConducted
Other,haveDeveloped
Other,haveIntroduced
Other,haveObserved
Other,haveProducedInLaboratories
Other,haveProposed
Other,haveProven
Other,havePublished
Other,haveReported
Other,haveReportedMainlyAfterMastectomy
Other,haveSuggested
Other,haveUsed
Other,haveValidatedByClinicalStudiesInCardiotoxicityDiagnosisInPatientsTreatedWithHighDosesOfAnthracyclinesAloneInCombinationMainlyWithTrastuzumab
Other,haveYetProven
Other,hazards
Other,hazardsOfBleeding
Other,hdgcTestingCriteria
Other,health
Other,healthcareCost
Other,healthcarePolicyMakers
Other,healthCareSector
Other,healthcareUtilization
Other,healthCenters
Other,healthExpectancyOfItspopulation
Other,healthInitiative
Other,healthySubjects
Other,healthyWaysOfLife
Other,HeLa
Other,helaCells
Other,hematoxylin
Other,henceCurrentlyOnlyRoutinelyImplementedInScreeningOfWomenAtIncreasedRiskOfBreastCancer
Other,henceMainlyBased
Other,her2/hrTripleNegativeTnmStages
Other,her2Expression
Other,her2Overexpressing
Other,her2-positiveA
Other,her2-positiveEarlyPatients
Other,her2Status
Other,her2-targetedTherapies
Other,herDisease
Other,hereditaryBreast
Other,hereditaryCausesOfChorea
Other,herPresentation
Other,heterogeneity
Other,heterogeneous
Other,heterogeneousCancerInFemalePatientsWorldwide
Other,heterogeneousPopulationsOfCellsWithHierarchicalOrganizationDrivenByCancerStemCells
Other,heterogenous
Other,hidden
Other,high
Other,highBurdenOfCancer
Other,highCorrelation
Other,higher
Other,higherDetectionRates
Other,higherDetectionRatesOfArchitecturalDistortionParticularlyInPatientsWithDenseBreastTissue
Other,higherProportion
Other,higher-qualityImaging
Other,higherRatesOfMisdiagnosisForBreastCancer
Other,higherResolution
Other,higherRisk
Other,higherRiskOfBleeding
Other,higherRisks
Other,higherRisksOfTreatmentDelays
Other,highestIncidenceAmongMalignanciesDiagnosedInWomen
Other,highestRateForUpperGastrointestinalCancers
Other,highestRisk
Other,highestSe
Other,highGlut1Expression
Other,highHeterogeneity
Other,highIndex
Other,highlightConsiderations
Other,highlightImportantConsiderations
Other,highlyEffective
Other,highlyExpressed
Other,highlyPenetrantGenes
Other,highlySensitiveNano-biosensor
Other,highMortalityRateForFemales
Other,highPercentageOfRemissionMaintenance
Other,high-riskWomen
Other,highVariability
Other,highVolumeAcademicCenters
Other,histologicalStructureOfTumorTissues
Other,histologicExamination
Other,histoneModifications
Other,histopathologicalAnalysis
Other,histopathologicalDiagnostics
Other,histopathologicalExamination
Other,histopathologicallyProvedBreastTumors
Other,histopathologicalreports
Other,histopathologicDistinction
Other,histopathologicFeatures
Other,history
Other,historyOfBreast-conservingSurgery
Other,historyPhysicalExamFindings
Other,hoechstStaining
Other,homologousRecombinationPathway
Other,hormone-dependentPositiveBreastCancer
Other,hospitalCohort
Other,hospitalFromJanuary2016ToFebruary2017
Other,hospitalizations
Other,hospitalizedBleedingRisk
Other,howeverElusive
Other,howeverHampered
Other,howeverHaveClarified
Other,howeverKnown
Other,howeverLargelyUnreported
Other,howeverMaySometimesDifficult
Other,howeverMuchLower
Other,howeverNon-ideal
Other,howeverShouldPerformed
Other,howeverSignificant
Other,howeverStillUnclear
Other,howeverSwitched
Other,howeverUnderutilized
Other,howeverWidelyUnderstood
Other,Hsa_circ_000178
Other,hsa_circRNA_102101
Other,hsa-miRNA-143-3p
Other,hugeImprovement
Other,hugeVolumes
Other,humanBiofluid
Other,humanBody
Other,humanBreastCancerCells
Other,humanBreastNeoplasmsWithDeregulationOfSeveralMirnas
Other,humanEpidermalGrowthFactorReceptor2ReceptorStatus
Other,humanErrors
Other,humanLife
Other,humanPapillomavirusScreening
Other,hundreds
Other,hybridChemicalProteomicsApproachTermedByEngineeringSrcHomology2
Other,hybridCultures
Other,hypomethylated
Other,hypomethylation
Other,hypomethylationSites
Other,hypothesis
Other,IC
Other,ICER
Other,ideallyPlaced
Other,identifiablePcrResults
Other,Identification
Other,identificationOfDistinctiveGeneticModificationsInDifferentBreastCancerMolecularSubtypes
Other,identificationOfPredictiveBiomarkersForSelectionOfOptimalTreatment
Other,identified
Other,identifiedAsMostEffectiveMolecules
Other,idiopathicGranulomatousMastitis
Other,illiterate
Other,imagery
Other,Images
Other,imaging
Other,imagingFeatures
Other,imagingFeaturesOfCommon
Other,imagingInvestigations
Other,imagingModalities
Other,imagingTechnique
Other,imbalance
Other,immediateReconstruction
Other,immediateUnmetNeed
Other,immediateUnmetNeedInClinicalPractice
Other,immune-mediatedCancer-associatedDisorders
Other,immunocaptureOfMarker
Other,immunocytochemicalStudies
Other,immunohistochemicalAnalysis
Other,immunohistochemicalProliferationMarkerKi67
Other,immunohistochemicalTechniques
Other,immunohistochemicalTests
Other,immunohistochemistry
Other,imperative
Other,implemented
Other,implications
Other,importance
Other,important
Other,importantAspect
Other,importantComponent
Other,importantComponentOfMitoticCheckpointMachineryHaveShownInSeveralCancersIncludingAnaplasticThyroidCancer
Other,importantContributors
Other,importantCopingResource
Other,importantCornerstone
Other,importantForDiagnosis
Other,importantInsightsIntoDiagnosisOfPatientsWithDisease
Other,importantIntercellularSignalingRegulatorWithExpressionCorrelation
Other,Importantly
Other,importantlyCouldPotentialDiagnosticBiomarkerInEthnicPopulation
Other,importantNumber
Other,importantOfSpc24ForClinicalTreatment
Other,importantPhenotypicFeatureOfCdh1GermlineMutationCarriers
Other,importantPotential
Other,importantProblem
Other,importantRole
Other,importantRoles
Other,improved
Other,improvedCancerTreatment
Other,improvedDetection
Other,improvedDiagnosis
Other,improvedDiagnostics
Other,improvedPatientOutcomes
Other,improvedQualityOfLife
Other,improvedUnderstanding
Other,improvement
Other,improvementInClassificationOfMalignantLesions
Other,IMR
Other,inAdditionFurtherConfirmedInEarlyStage
Other,inAdditionMeasured
Other,inadequate
Other,inBelgiumMostFrequentWomen'sCancerAccountingForTo353PercecntOfCases
Other,inBreastTumorsKnownAsBreastCscs
Other,inCanadaOfferedInOrganizedPrograms
Other,inception-v3Cnn
Other,incidence
Other,incidenceAmongMalignancies
Other,incidenceFactors
Other,incidenceFactorsOfSubsequentLung/bronchusPrimaries
Other,incidenceOfCancer
Other,incidenceOfCardiovascularDiseaseAmong32757CancerSurvivors
Other,incidenceRates
Other,incision
Other,inclined
Other,included
Other,included.When
Other,including
Other,inclusion
Other,inclusionCriteria
Other,inclusions
Other,inColorectalCancersHaveConducted
Other,inconsistentResults
Other,inContextAppliedInClinicalDiagnosticsInClinicalTrialsForPurposeOfStratification
Other,incorrectDiagnosis
Other,increase
Other,increased
Other,increasedDifferentiation
Other,increasedMalignantPotential
Other,increasedPer2Expression
Other,increasedRisk
Other,increasedRiskOfEndometrialCancer
Other,increasedRiskOfLong-termIncidentcvd
Other,increasedRiskWithUseOfLevonorgestrelIntrauterineSystem-bothOfPotentiallyImportantFindings
Other,increasedRonExpression
Other,increases
Other,increasingNumber
Other,incrementalCostOfCop$251049
Other,independent
Other,independentPrognosticFactor
Other,independentPrognosticFactorForDfsOfEarlyStageBreastCancer
Other,independentReviewers
Other,indicated
Other,indicationsForRisk-reducingSurgery
Other,indicative
Other,indicator
Other,indispensable
Other,individualRiskOfRecurrence
Other,individuals
Other,induction
Other,inductionOfFamily
Other,inexpensive
Other,inexpensiveTechnique
Other,infiltrationSimilar
Other,inflammatory
Other,inflammatoryBreastDiseaseWithUnknownEtiology
Other,inflammatoryDiseases
Other,influences
Other,Information
Other,informationalNeedsByCancerType
Other,informationNeeds
Other,informationNeedsVary
Other,inGrowth
Other,inheritableBi-objectiveCombinatorialGeneticAlgorithm
Other,inherited
Other,inhibited
Other,inhibition
Other,inhibitors
Other,inHumanBreastCancerHasReported
Other,inImaging
Other,initialPresentationOfInvasiveBreastCancer
Other,initialResults
Other,initialTreatmentAfterWhich
Other,initiationOfBreastMalignancy
Other,initiationOfPromptTherapy
Other,inLongTermHasFound
Other,inMarch2014BroadcastedAsPart
Other,inMultivariateModelsRelatedToPerformanceStatus
Other,innateImmuneSystems
Other,inOfGamma-ggtTransformedIntoNir-sn-nh
Other,inPaperUsed
Other,inPreprocessingHasAchieved
Other,insight
Other,insights
Other,inspection
Other,insufficient
Other,intelligentTechniques
Other,intensive
Other,interaction
Other,interactionEffects
Other,interest
Other,interleukin6
Other,interplay
Other,interpretation
Other,interview
Other,intopreGroups
Other,inTotalMatchedToCasesOnBirthYear
Other,intralaboratoryValidationSet
Other,intravoxelIncoherentMotionParameters
Other,invasion
Other,invasive
Other,invasiveCarcinomaBreast
Other,inverseLongitudinalAssociation
Other,inverselyCorrelated
Other,inverseProblem
Other,investigate
Other,investigated
Other,investigatedOnly
Other,Investigation
Other,invitedInputFromExpertsInSpecificAreas
Other,involved
Other,involvement
Other,involvementOfPtenInCs
Other,ipsilateralBreastRecurrence
Other,iraqiWomenWhencomparedToWesternWorld
Other,ironOxideNanoparticles
Other,Irradiation
Other,isIdentified
Other,Isolation
Other,Israel
Other,isReplaced
Other,isReplacedWithRadiotherapyInSituations
Other,It
Other,itEffects
Other,iterativelyModified
Other,itInvolvesInManyCrucialMetabolicProcesses
Other,its
Other,itsDeregulation
Other,itsDifficultEarlyDiagnosis
Other,itsExpression
Other,itsImportantRole
Other,itsImportantRoleInEtiologyOfManyDiseases
Other,itsMinimalSilverIonReleaseProfiles
Other,itsPoorPrognosis
Other,itsReceptorLocatedInManyCellsOfBody
Other,itsRelativeClinicalSignificance
Other,itsRelevantLimitations
Other,itsRole
Other,itsUse
Other,itsUsefulness
Other,itsWidespreadUse
Other,iU22
Other,ivimParameters
Other,jak-statPathway
Other,january1998June2017
Other,Japan
Other,Japanese
Other,kaplanMeierCurves
Other,kaplan-meierCurves
Other,Kazakhstan
Other,Kenya
Other,Ki67
Other,Kiel
Other,kind
Other,kmt2aFusionGenes
Other,kmt2aFusionGeneTranscripts
Other,knockdown
Other,know-howWe
Other,knowledge
Other,knowledgeGaps
Other,knowledgeOfM
Other,knowledgeSummaries
Other,known
Other,knownHeterogeneousDisease
Other,l-3
Other,l-3Knockdown
Other,label-freeDetection
Other,Lack
Other,lapatinibCombined
Other,large
Other,largeBreastCancerTissueMicroarray
Other,largelyConsistent
Other,largelyUnknown
Other,largeNumberOfTumor-freeData
Other,largerStudies
Other,large-scaleStudies
Other,largestCancerInformationWebsite
Other,largestCancerPatientCohortStudies
Other,largestReviewOnPrsInAsianPopulation
Other,largeVariability
Other,late-phaseClinicalTrials
Other,learning
Other,least
Other,leastAbsoluteShrinkage
Other,leaves
Other,leftParietalRegion
Other,lentivirusTransduction
Other,lesions
Other,lessBleeding
Other,lessBleedingThanTraditionalVenousThromboembolismInGeneralPopulation
Other,lessEffective
Other,less-effectiveChemotherapyAgents
Other,lessLikely
Other,lessVisits
Other,leucocytes
Other,levels
Other,levelsOfEralphaProtein
Other,life
Other,life-threatening
Other,likely
Other,likelyParaneoplastic
Other,limitations
Other,limited
Other,limited-angleFourier-domainSosReconstruction
Other,limitedHealthSystemCapacities
Other,limitedNumberOfCases
Other,linkage
Other,linked
Other,lipidProfiles
Other,lisbonRegion
Other,Literature
Other,little
Other,littleSurvivalVariance
Other,LMICs
Other,lobularCarcinoma
Other,localEntropyMaximizationAlgorithm
Other,localExcision/lumpectomy
Other,localizedDescription
Other,localizedDescriptionOfBreastCancer
Other,locallyAdvancedBreastCancer
Other,localRecurrence
Other,localTherapy
Other,localTherapyOfBreastCancer
Other,locoregionalDiseaseOfUnspecifiedLocation
Other,locoregionalRadiotherapy
Other,logisticregressions
Other,longerPfs
Other,longitudinalAssociation
Other,longNoncodingRnas
Other,longScanTime
Other,long-term
Other,long-termEstimates
Other,long-termUse
Other,loss
Other,lossOf020Quality-adjustedLifeYears
Other,lowClassificationAccuracies
Other,lowCountries
Other,lowCtnLevels
Other,lower
Other,lowerNewBloodVesselsFormation
Other,lowIncidence
Other,lowIncomeCountries
Other,low-molecular-weightHeparin
Other,lowRiskLesions
Other,lumbarSegments4-6
Other,luminalB-likePatients
Other,lung/bronchusMalignancies
Other,lungCancerInHuman
Other,lymphaticInvasion
Other,lymphedemaseventyPatients
Other,lymphNodeMetastasisInPatientsWithBreastCancer
Other,lymphNodeRatio
Other,lymphocytes
Other,M
Other,mab1e3
Other,made
Other,magneticResonanceImaging
Other,main
Other,mainChallenge
Other,mainContribution
Other,mainlyEurope
Other,mainlyExpressed
Other,mainlyObserved
Other,mainlyPostmenopausalWomen
Other,mainMeasures
Other,mainObjective
Other,maintainedBreastCancerDatabase
Other,maintenance
Other,maintenanceOfErCancerStemCells
Other,mainTwoEntities
Other,major
Other,majorAdvance
Other,majorConcerns
Other,majority
Other,malePatients
Other,malign
Other,malignantProgressionOfBreastCancer
Other,mammalianBrainTissues
Other,mammograms
Other,mammographicBreastCancerScreening
Other,Mammography
Other,managed
Other,Management
Other,managementOfTumour-relatedSymptoms
Other,manifold
Other,manyBreastCancerPatients
Other,manyComputerVisionApplications
Other,manyFeatures
Other,manyPatients
Other,manyResearchers
Other,manyWays
Other,manyWomen
Other,mapped
Other,mappedToPatientPathway
Other,markedlyDownregulated
Other,markedlyUp-regulated
Other,markedReduction
Other,markerBands
Other,mass/es
Other,masses
Other,mastectomizedWomen
Other,mastectomy
Other,mastitis
Other,matched
Other,matchedHealthyTissues
Other,materialDetection
Other,matthewsCorrelationCoefficientOf8038Percecnt
Other,mayDetected
Other,mayImportantStepsDuringDiagnosis
Other,mayNecessary
Other,maySteps
Other,mayUsed
Other,mayUsedForTumourShrinkagePriorToSurgery
Other,MCC
Other,mda-mb-231Cells
Other,mda-mb-231CellsMeasuredBy3
Other,mean
Other,meanTime
Other,measured
Other,measurements
Other,measurementSystem
Other,measures
Other,mechanism
Other,mechanisms
Other,medianOs
Other,medianOverallSurvival
Other,medianProgression-freeSurvival
Other,medianTime
Other,medical
Other,medicalDiagnosisOfBreastCancer
Other,medicalHistory
Other,medicalKnowledge
Other,medicalStatus
Other,medications
Other,MEDLINE
Other,member
Other,members
Other,menopause
Other,meta-analyses
Other,metabolicChanges
Other,metabolicTargetVolume
Other,metabricTrainingSet
Other,metastasectomy
Other,Metastases
Other,metastasesFromDistantPrimaryTumors
Other,metastasis-free
Other,metastatic
Other,metastaticAdenocarcinomaFeatures
Other,metastaticBreastCancer
Other,metastaticDisease
Other,MetastaticLesions
Other,method
Other,methodologyOfInstitutoDeEvaluaciónTecnológicaEnSalud
Other,METHODS
Other,methodsDesign
Other,methylation
Other,methylationStatus
Other,methylationStatusOfPcdh10InBreastCancerTissues
Other,MethyLight
Other,methylSpecific-multiplexLigationProbeAmplification
Other,miceConditions
Other,microadenomasDataOnLong-termRemissionRate
Other,microfluidicChips
Other,microfluidicPlatform
Other,microRNA
Other,microrna-22ExpressionLevels
Other,microRNAs
Other,microscopicTesting
Other,mightPromisingTherapeuticStrategyForHormone-therapyRefractoryEr
Other,mightUseful
Other,migration
Other,migrationAbilitiesOfCervicalCancerCells
Other,migrationAbilitiesOfHelaCells
Other,mildHyperthermia
Other,minimalRedundancyMaximalRelevanceAlgorithmAsFeatureSelectionMethods
Other,minimalRisksToNormalCells
Other,mir-10aExpression
Other,mir-193b-3pBinding
Other,mir-193b-3pBindingTo3UntranslatedRegionOfMorc4
Other,mir-193b-3pIdentifiedAsRegulator
Other,miR-34s
Other,miR-511
Other,mir-511Expression
Other,mir-511Overexpression
Other,miRNA
Other,mirnaExpressionProfiles
Other,miRNAs
Other,misdiagnosis
Other,missed
Other,mistaken
Other,mitochondrialFission
Other,mitosis
Other,mitosisDyingByMitoticCatastrophe
Other,mixedMethodsDesign
Other,mmp2Genes
Other,modeled
Other,modelling
Other,modificationPathways
Other,modified
Other,modulated
Other,molecular
Other,molecularAnalyses
Other,molecularChanges
Other,molecularDiagnosisMethodMake
Other,molecularRegulatoryNetworks
Other,molecularTesting
Other,monitored
Other,monitoredOnDailyBasis
Other,monteCarloFeatureFeatureMethod
Other,monteCarloFeatureSelection-basedFeatureSelection-basedComputationalMethod
Other,mood
Other,moodOfLife
Other,morc4Silencing
Other,morcFamilyCw-typeZincFinger4Overexpression
Other,moreAdvancedStages
Other,moreAdvancedStagingAtDiagnosisInWomen
Other,moreCommonlyDiagnosed
Other,moreDesirable
Other,moreDirectional
Other,moreEasilyHypomethylated
Other,moreEffectiveTreatmentOfLungCancers
Other,moreInclined
Other,moreInformationAboutFurtherStratificationOfBreastCancerSubtypes
Other,moreLikely
Other,moreoverAssociated
Other,moreoverMostOfTimeBenignRequired
Other,moreoverPoor
Other,moreoverSignificantlyLower
Other,moreoverStronglyRecommended
Other,moreRecentlyHaveDeveloped
Other,moreRecommended
Other,moreRefinedStratificationThanAnatomicStageAlone
Other,moreTargetedAdjuvantTreatments
Other,mortality
Other,mortalityRate
Other,mortalityRates
Other,most
Other,mostBreastDiseases
Other,mostCases
Other,mostCommonAdultCancersInKenya
Other,mostCommonAgentsUsedInBreastCancerTreatment
Other,mostCommonCancer
Other,mostCommonCancerInWomen
Other,mostCommonlyDue
Other,mostCommonMalignantTumor
Other,mostCommonNeoplasms
Other,mostCommonOnes
Other,mostCommonUltrasonographicFindings
Other,mostEffectiveTechniqueused
Other,mostEuropeanCountries
Other,mostFrequentCancer
Other,mostFrequentCancerInWomenTreatedWithHormonalTherapy
Other,mostFrequentlyDiagnosedCancer
Other,mostFrequentlyObserved
Other,mostFrequentMalignancy
Other,mostFrequentMetastaticTumors
Other,mostInvasiveDisease
Other,mostInvolvedSegmentsWithSuvmax39
Other,mostLikelyParaneoplastic
Other,mostlyBilateral
Other,mostOfPatientsDuringMammography
Other,mostPatients
Other,mostPervasiveTypeOfCancerAmongWomen
Other,mostPowerfulTool
Other,mostPretermBirth
Other,mostPrevalentCancer
Other,mostPrevalentMalignancyAmongWomenAroundWorldAreDiagnosedYear
Other,mostPrevalentMalignancyDiagnosedInPregnancy
Other,mostPrevalentTumorFollowedByLow-gradeBNon-hodgkinLymphoma
Other,mostPrevalentType
Other,mostRelevantKind
Other,mostSensitiveTest
Other,mostSensitiveTestForBreastCancerDetection
Other,mostStudies
Other,mostToxic
Other,mostTumors
Other,mothers
Other,motivated
Other,MP
Other,mPatients
Other,mpMRI
Other,MRI
Other,mriImaging
Other,mriProtocols
Other,mriTechniques
Other,mrnaLevels
Other,mrSystems
Other,mStage
Other,muchFocus
Other,muchInterest
Other,multigenePanels-with
Other,multiparametricMri
Other,multipleBiological
Other,multipleBiologicalRolesIncludingParticipationInImmunosuppressiveStudies
Other,multipleGeneticAberrances
Other,multipleMitochondrialMetabolicPathways
Other,MultipleMyeloma
Other,multiplexPlatform
Other,multiresolutionResult
Other,multivariate
Other,multivariateModelsAdjustedForIncome
Other,multiyearCollaborationLedByUnionForInternationalCancerControl
Other,murineMonoclonalAntibodies
Other,mustAddressed
Other,mustAddressedDuringCancerGeneticCounselingConsultations
Other,mustIndividualized
Other,mutationalStatusBesidesFamilyHistory
Other,mutationCarriers
Other,mutationEvents
Other,mutationRatio
Other,mutations
Other,mutationsCarriers
Other,Myeloma
Other,nano-biosensor
Other,nano-genosensor
Other,nanoparticels
Other,napsinAIn7Percecnt
Other,nationalTrials
Other,nationwideRegistries
Other,nationwideSurvey
Other,nature
Other,NCCN
Other,near-infraredLight-controllable
Other,necessary
Other,necessity
Other,need
Other,needed
Other,neededAcrossCareContinuumEspeciallyInLow-resourceSettings
Other,needForAnalysisOfMetastaticTissuesAtRecurrence
Other,needForNodalRadiotherapyInSpecificSituations
Other,needs
Other,needsInPrevention
Other,needsOfInformationSeekers
Other,negative
Other,negativeEffects
Other,negativeIndicator
Other,negativelyCorrelatedWithLvef
Other,negativeMargins
Other,neglected
Other,neoadjuvantAnti-her2Treatment
Other,neoadjuvantChemotherapy
Other,neoadjuvantChemotherapyGroups
Other,neoadjuvantTreatment
Other,neonatal
Other,neonatalOfRetrospectiveCohortOfPregnantWomenWith
Other,netherlandsCancerRegistryOf37230PatientsWithEarlyBreastCancer
Other,networkOutput
Other,networks
Other,neuralNetworkClassifier
Other,neurocognitiveSequelae
Other,neutralEffects
Other,neutrophil-to-lymphocyteRatio
Other,newCancerCases
Other,newDesignDouble-layerCapacitors
Other,newFpReductionTechnique
Other,newOpportunitiesForDevelopmentOfNovelTherapeuticStrategies
Other,news
Other,newSignalPattern
Other,newValue-basedHealthcareParadigm
Other,nextMade
Other,nf-krab-inducedIncreasedExpressionOfCcnd1
Other,nippleInvolvement
Other,NLR
Other,NMA
Other,node
Other,none
Other,non-ideal
Other,noninvasive
Other,noninvasiveImaging
Other,noninvasiveImagingTechniqueForBreastCancerDiagnosis
Other,Non-linearity
Other,normalCardiacFunction
Other,normalDucts
Other,normalSamples
Other,normalTissues
Other,notablyDesigned
Other,notablyUpregulatedWithinPatients
Other,noted
Other,novel
Other,novelInsightsIntoEpigeneticEvents
Other,novelInsightsIntoPotentialMechanismsAssociatedWithBreastCancerPathogenesis
Other,novelMethod
Other,novelPowerfulTechnique
Other,novelTargetedTherapeuticOptions
Other,novelTherapeuticBiomarkerForDiagnosis
Other,novelty
Other,now89Years
Other,nowAlsoWidelyUsed
Other,nowGreater
Other,nsclcPatientsAssociatedWithShorterOverallSurvival
Other,nsclcSamples
Other,n-typeVoltage-gatedV-gCalciumChannelBindingAntibodies
Other,nuclearFactors
Other,number
Other,numberOfLong-termSurvivors
Other,numberOfSegmentInvolved
Other,numberVariants
Other,numericalFull-waveSimulation
Other,numerousGene-expression-basedPrognosticSignatures
Other,numerousStudies
Other,objective
Other,objectives
Other,observationalStudies
Other,observed
Other,obstetrician
Other,obstetricians
Other,obtained
Other,obtainedFeatures
Other,obtainedFrom66FemalePatientsWithMAtDifferentTimeIntervalsForEvaluationOfCtcsByFlowCytometry
Other,obtainedFromMedicalSpecialists
Other,obtainedFromPatientsWithBreastCancer
Other,occultBreastTumors
Other,occurrence
Other,occurrenceOfBreastCarcinoma
Other,occurrenceOfTumors
Other,occurring
Other,occurringCancers
Other,ODV
Other,oestrogenReceptorCofactors
Other,oestrogenReceptorPositiveIn58PercecntOfCasesPositiveIn62Percecnt
Other,of121Patients
Other,offered
Other,oftenDebated
Other,oftenHypomethylated
Other,oftenRelated
Other,old
Other,olderAdultsWith
Other,olderWomen
Other,omegaFattyAcids
Other,omission
Other,oncogene
Other,oncogenes
Other,oncogenesEsr1
Other,oncologicRisk
Other,oncology
Other,oncologyGroup
Other,oncoproteins/cancerSuppressors
Other,oneCancer
Other,oneExtraVisit
Other,oneFamilyAffectedByCs
Other,oneHundredElevenPatients
Other,oneMutation
Other,oneRandomlyAssignedToAxillaryDissection
Other,oneRegion
Other,oneRegionAnother
Other,onEsophagogastroduodenoscopyIdentifiedInAntrum
Other,oneSpecificSubtype
Other,one-thirdCases
Other,oneYear
Other,ongoingTrials
Other,online
Other,only1ulOfSerumSample
Other,only20Percecnt
Other,only35Cases
Other,only44Percecnt
Other,onlyIndicated
Other,onlyIndicative
Other,onlySubgroupWithProgesteroneReceptor
Other,onlyWomen
Other,Ontario
Other,operablePatients
Other,opportunities
Other,opportunitiesForResearchInBreastSurgery
Other,opticalAbsorptions
Other,optimalCut-offValue
Other,optimalCutoffValues
Other,optimalParametersInFeatureSelectionProcess
Other,optimalTherapeuticTargetForPatientWithAdvancedBreastCancer
Other,options
Other,OR
Other,oralBeta-sdgAdministration
Other,organotropic
Other,ORR
Other,osAdvantage
Other,osRate
Other,OSs
Other,osteopontin-750Accumulation
Other,osteopontinPeptide
Other,otherData
Other,otherDietaryRecommendations
Other,otherFactors
Other,otherImagingCharacteristics
Other,otherInotherTertiaryCentres
Other,others
Other,otherSignificantConcerns
Other,otherSites
Other,otherSubtypesOfBreastCancer
Other,otherTwoGroups
Other,ourAim
Other,ourBreastCancerPatients
Other,ourData
Other,ourFacility
Other,ourFindings
Other,ourMethod
Other,ourPatient
Other,ourProposedMethod
Other,ourResults
Other,ourTheoreticalAnalysis
Other,outcome
Other,outcomeOverCosts
Other,outcomes
Other,outcomesAmongKoreanPatients
Other,outcomesOfEstrogenReceptorPositive
Other,outliers
Other,outpatientClinic
Other,output
Other,ovarianMetastases
Other,overallCumulativeRiskOfProgression
Other,overallLowOfSixCirculatingMirnas
Other,overallMedianSurvival
Other,overallMediumSecondTumor-freeTime
Other,overexpressed
Other,overexpression
Other,overnight
Other,over-represented
Other,overview
Other,overviewOfAbbreviatedBreastMriProtocols
Other,oxidationPeakCurrent
Other,P
Other,painless
Other,painlessLumpInBreastAccountingFor688PercecntOfPatients
Other,pairedTumor
Other,palliativeChemotherapy
Other,paper
Other,paradigmaticExamples
Other,parallelDetection
Other,parameters
Other,parameterUncertainty
Other,parpInhibitors
Other,part
Other,particleSwarmOptimizationAlgorithm
Other,particular
Other,particularEmphasisQuantifying
Other,particularlyPatientsWithDenseBreastTissue
Other,particularlyPertinent
Other,pathogenesisOfBreastCancer
Other,pathogenic
Other,pathogenicVariantsInBrca1/2
Other,pathologicallyTumor-freeNodes
Other,pathologicalResults
Other,pathologicalSpecimen
Other,pathologicEvaluation
Other,pathologistAnnotation
Other,pathway
Other,pathways
Other,Patients
Other,patientsByTrastuzumab-pretreatment
Other,patientSelectionForNon-pcosReferenceCohort
Other,patientsFrom10Countries
Other,patient'sHistory
Other,patient'sMedicalHistory
Other,patients'MedicalRecords
Other,patients'MedicalRecordsFromOctober2007ToDecember2012
Other,patientsOnAromataseInhibitors
Other,patient'sOutcomeOverCosts
Other,patients'Self-monitoring
Other,patient'sTumorBurden
Other,patientsWithBreastCancer
Other,patientsWithBreastCancerReceivingWithAnthracyclines
Other,patientsWithCancer
Other,patientsWithHer2
Other,patientsWithHistoryOfBreastSurgery
Other,patientsWithLocoregionalInSouthernPortuguese
Other,patientsWithMAmongThem
Other,patientsWithMeasurementErrors
Other,patientsWithMetastaticBreastCancer
Other,patientsWithNeoplasticDisease
Other,patientsWithProlactinoma
Other,patientsWithSmall-cellLungCancer
Other,patientWithEarlyBreastCancer
Other,paTreatment
Other,pattern
Other,patterns
Other,patternsOfAssociationResults
Other,pax6GeneExpression
Other,pax6Inhibition
Other,pax6MethylationStatus
Other,pax6Overexpression
Other,pax6promoterMethylation
Other,pax8AMetastasesOfCancer
Other,pb-ctMode
Other,PB-DLL
Other,pcdh10GenePromoterMethylationIdentifiedInDuctalCarcinoma
Other,PCI
Other,pcosGroups
Other,pcrResults
Other,pD1542yMissenseMutation
Other,pdgfs/pdgfrsAxis
Other,peakInRecurrenceRisk
Other,peopleWithDiagnosisOfCancer
Other,per2Expression
Other,percecnt
Other,percecntConfidenceIntervals
Other,percecntRelapsedTissues
Other,percent
Other,percentage
Other,perceptionOfQualityOfCareProvidedByCancerCareNetworkForEarlyDetectionOfBreastCancer
Other,perfluorohexane
Other,performed
Other,performedFromInceptionToJanuary312018
Other,peripheralBlood
Other,peripheralBloodSamples
Other,persistentPain
Other,personalDecision-making
Other,pertinent
Other,PF
Other,pfBiomarkers
Other,PFH-PTX@PLGA
Other,pfh-ptx@plgaSpio-her
Other,PFS
Other,pharmacokineticParameters
Other,pharmacokineticProperties
Other,pharmacologicalInduction
Other,phosphatase
Other,phosphoinositide3-kinase
Other,phosphorylation
Other,phosphorylationOfAkt
Other,physicallyActive
Other,physician
Other,PI3K/AKT/mTOR
Other,pi3k/aktKinasePathway
Other,pi3k/aktSignaling
Other,pi3k-akt-mediatedMitochondrialSignalingPathwayTumorSuppressorMir-10a
Other,pi3k-aktSignalingPathway
Other,picture
Other,pik3caMutations
Other,pitfall
Other,place
Other,placed
Other,planning
Other,plasmaLevels
Other,platform
Other,PM
Other,policyActions
Other,poly
Other,polymeraseChainReaction
Other,polymorphism
Other,polymorphismOfFok1
Other,pool
Other,pooledUptake
Other,poor
Other,poorerPrognosisInPatients
Other,poorPrognosis
Other,popular
Other,population
Other,population-basedStudies
Other,populations
Other,portugueseWomen
Other,positive
Other,positiveChanges
Other,positiveFeedbackLoop
Other,positiveForGata3In93PercecntIn78PercecntOfCases
Other,positiveHer2Expression
Other,positivelyAssociated
Other,positivelyCorrelated
Other,positiveRegulatoryFeedbackLoopForFxyd3Amplification
Other,positiveTreatment
Other,positronEmissionTomography
Other,possibility
Other,posteriorFossaOfBrain
Other,postmenopausalPatient
Other,postmenopausalWomen
Other,post-menopausalWomen
Other,postmenopausalWomenWithDevelopmentOfBreastCancer
Other,post-radiationVascularLesions
Other,potato
Other,potentAnticancerEffects
Other,potential
Other,potentialBiomarker
Other,potentialBiomarkerForCancerDiagnosisThanMrnaBiomarkers
Other,potentialClinicalBiomarker
Other,potentialForOverdiagnosis
Other,potentialImportanceAsModelsForHumanBreastCancer
Other,potentiallyCurativeRegimensOfCancerChemotherapy
Other,potentialMechanism
Other,potentialMechanismForFoxc1-inducedMetastasis
Other,potentialReduction
Other,potentialSourcesOfVariance
Other,potentialTarget
Other,potentialTherapeuticTarget
Other,potentialTreatmentStrategy
Other,potentialTreatmentStrategyForEndocrine-resistantBreastCancers
Other,potentNon-secosteroidalVdrModulator
Other,powerfulToolForEarlyDetection
Other,practicePatterns
Other,practitionerDecisionmaking
Other,practitionersKnowledgeable
Other,pragmaticApproachToPopulation-basedCancerScreening
Other,pre
Other,preciseToolForTargetedTreatmentOfCancerIncluding
Other,precision
Other,preclinicalModels
Other,preclinicalPhase
Other,pre-diagnosticObesity
Other,predicted
Other,prediction
Other,predictive
Other,predictors
Other,predominant
Other,predominantlyCystic
Other,pregnancy
Other,pregnancyFrom1959To1966
Other,pregnancyOutcomes
Other,preoperativeUnderstanding
Other,preparedRespectively
Other,presence
Other,presenceOfTendinopathy
Other,present
Other,presentation
Other,presented
Other,preservationOfBiomarkerExpressionInOldFfpeTumour
Other,Prevalence
Other,prevalenceOfobesityOf277Percecnt
Other,prevalent
Other,prevention
Other,preventionOfBreastCancer
Other,preventionOfDiagnosedBreastCancerInEstrogen-aloneArmOfWhi
Other,preventiveStrategies
Other,previousStudies
Other,previousTherapy
Other,primaryBreastCancer
Other,primaryBreastCarcinoma
Other,primaryCareProvider
Other,primaryPurposeOfPeriodicMammogramsInScreeningProgramsIs
Other,primaryTumours
Other,principles
Other,priorities
Other,priorMedicalHistory
Other,probableAnticancerMechanisms
Other,probableMechanisms
Other,Probes
Other,problem
Other,processing
Other,product
Other,profile
Other,profiles
Other,prognosesOfYoungMenWithBreastCancer
Other,prognosis
Other,prognosisMoreAccurately
Other,prognosisOfPatientsWithMaleBreastCancerInShanxiProvinceOfChinaFrom2007To2016
Other,prognostic
Other,prognosticFactorIndependentOfOtherClinicalVariables
Other,prognosticFactorsOfCancerProgression
Other,prognosticSignificanceOfNeutrophil-to-lymphocyteRatioInPatientsWithBreastCancer
Other,prognosticSignificanceOfNlrInEarlyStage
Other,prognosticStagingSystems
Other,prognosticValue
Other,program
Other,programs
Other,progression-freeSurvival
Other,progressionOfSeveralTypesOfNeoplasms
Other,progressionOfTumorInvasionInBreastCarcinoma
Other,prohibitivelyExpensive
Other,project
Other,projected
Other,proliferation
Other,prominent
Other,promising
Other,promisingBiomarkers
Other,promisingNoninvasiveBiomarkerForDetectionOfDiseases
Other,promisingNon-invasiveReal-timeSurrogatesForCancerDiagnosis
Other,promisingShort-termStrategiesPriorToTreatmentAdministration
Other,promisingSupplements
Other,promoterdnaMethylation
Other,promoterMethylationInCertainTypesOfHumanTumors
Other,promoterMethylationStatus
Other,Promoting
Other,propagation-basedPhase-contrast
Other,propensityScoreMatchingAnalysis
Other,properAccessToDiagnosis
Other,properFunctioningOfSkeletalSystem
Other,properties
Other,prophylacticBilateralSalpingo-oophorectomy
Other,prophylacticCranialIrradiation
Other,proportion
Other,proposed
Other,proposedAlgorithm
Other,proposedForBreastTumorGrading
Other,proposedHowever
Other,proposedMethod
Other,proposedTechniqueResults
Other,prospectiveInformationAboutCharacteristicsOfWomenWithLungCancer
Other,prospectivelyFollowedFor3YearsSinceDiagnosis
Other,prospectiveStudies
Other,prostateCancers
Other,protected
Other,protectiveFactors
Other,protectiveRoleOfRs5743810
Other,proteinExpression
Other,proteinExpressionOfNf-krab-p65
Other,proteinKinaseC/extracellularSignal-regulatedKinasePathway
Other,proteinKinaseC/extracellularSignal-regulatedKinasePathwayInSpinalCordInLumbarSegments4-6
Other,proteinKinaseCInhibition
Other,proteinKinaseCInhibitors
Other,proteinLossOfPtenByPhosphorylation
Other,proteins
Other,proteinS-100
Other,protocol
Other,protocols
Other,provedByExperimentalEvidence
Other,proxyForcvd
Other,pseudotumoralAspect
Other,psychologicalAspects
Other,ptyrProteins
Other,public
Other,publicHealthCareSystem
Other,publicHealthChallenge
Other,pulmonaryMetastases
Other,purpose
Other,putativeBiomarkerForDetectionOfVariousHumanDiseases
Other,pyrrolizin-9-one
Other,Pyrrolizinones
Other,q12X
Other,QALY
Other,qualitativeApproach
Other,quality
Other,qualityOfLife
Other,quantified
Other,quantitative
Other,queried
Other,questionnaireAdministeredOnJapan'sLargestCancerInformationWebsite
Other,racialDisparity
Other,radiation
Other,radicalSurgicalApproaches
Other,radiomics
Other,radiomicsScore
Other,Radiotherapy
Other,Rainbow
Other,randomisedTrials
Other,randomlyDivided
Other,random-samplingMethod
Other,ranging
Other,rapidAdvancements
Other,rapidBreast-cancer-tissueDiagnosis
Other,rare
Other,rareCases
Other,rarelyMayDetected
Other,rareSubtypeOfDllWithLimitedDataOnPatternsOfFailure
Other,rareTumor
Other,rate
Other,rateIncrease
Other,rates
Other,ratio
Other,realDataAnalysis
Other,reality
Other,realStatusOfPrs
Other,real-worldSetting
Other,receivedWithoutSurfaceModification
Other,receiving
Other,recentDevelopments
Other,recentEpigenomeStudies
Other,recentlyDevelopedBreastImagingTechnique
Other,recentlyDiagnosedBreastCancer
Other,recentlyHaveUsedAsBiomarkers
Other,recentPatternsInIncidenceRatesForMajorCancerSitesInAdults
Other,recentStudies
Other,recentYears
Other,receptorActivator
Other,receptorTyrosineKinasePdgfrb
Other,recognized
Other,recognizedAsCtcIn1Of15HealthyBloodSamples
Other,recognizingMethylationStatus
Other,recommendations
Other,recommended
Other,records
Other,recruitment
Other,recruitmentOfOlderAdults
Other,recurrence
Other,recurrence-free-survival
Other,recurrenceRates
Other,Recurrences
Other,recurrentHyperprolactinemia
Other,recursiveFeatureElimination
Other,redoxStatus
Other,reduction
Other,reductionOfFpsFrom085002Fp/imageForMias
Other,reference
Other,referenceForClinicians
Other,referral
Other,Referrals
Other,registered
Other,regressionAnalyses
Other,regulated
Other,regulationMechanisms
Other,regulationOfEmtProgressionOfSnaiFamilyMembers
Other,regulationOfEnergyMetabolism
Other,regulationOfNras
Other,relapseRates
Other,related
Other,relatedResearchDataOfDiagnosisOfInoperableLocallyAdvancedBreastCancer
Other,relatedTranscriptionFactorSox9
Other,relation
Other,relationship
Other,relationshipBetweenNlr
Other,relationshipBetweenStromalExpressionOfPodoplaninInInvasiveBreastCarcinoma
Other,relativeHospitalizedBleedingRisk
Other,relativelyGoodPrognosisWith5YearOverallSurvivalOf88Percecnt
Other,relativesOfPatientsWithPa
Other,relativeThoseOfControls
Other,relevant
Other,remarkableImprovements
Other,remodeled
Other,repair
Other,replaced
Other,report
Other,reported
Other,reportedInSignificantlyHigherProportionOfPatientsWithPa
Other,reporterAssays
Other,reports
Other,represented
Other,reproducingKernelHilbertSpace
Other,required
Other,research
Other,researchDevelopment
Other,Researchers
Other,resectedPrimaryLungCancer
Other,Residents
Other,resistant
Other,resistantCells
Other,resistantToExonuclease-mediatedDegradation
Other,resonanceImaging
Other,resources
Other,respectivelyFound
Other,respondents
Other,responsible
Other,responsibleMechanisms
Other,restoration
Other,result
Other,resultCompatibleWithMetastasisToOrbit
Other,resultOfPresentationWithAbnormalUterineBleeding
Other,resultOfPreviousOrbitalBiopsy
Other,results
Other,resultsAberrantExpression
Other,resultsDiagnosed
Other,resultsExpression
Other,Resurgery
Other,retrieved
Other,retrospective
Other,retrospectivelyReviewed
Other,retrospectiveReview
Other,retrospectiveStudies
Other,revealed
Other,reverseActiveLearningForClassificationOfHealthyBreastTissue
Other,reverseTranscriptionQuantitativePolymeraseChainReaction
Other,reverseTranscription-quantitativePolymeraseChainReaction
Other,review
Other,reviewed
Other,revisionsOfAjccBreastCancerStagingSystem
Other,RFFS-GS
Other,richSpectralFeaturesOfPhenyboronicAcid-basedNanoprobe
Other,right4
Other,rightMastectomyWithSentinelLymphNodeBiopsy
Other,risingTrendInMajorityOfLmics
Other,risingTrendOfColorectalCancers
Other,Risk
Other,riskFactor
Other,riskFactorForLung/bronchusCancer
Other,riskFactors
Other,riskForRecurrence
Other,riskOfBreastCancer
Other,riskOfBreastCancerInAdulthood
Other,riskOfDeath
Other,riskOfDevelopmentOfGliomas
Other,riskOfEndometrialPathologies
Other,riskOfOtherLongTermAdverseHealthSequelae
Other,RiskProtection
Other,risk-reducingStrategies
Other,risks
Other,risksOfCancerInMutationsCarriers
Other,riskStratification
Other,risk-stratifiedScreeningStrategy
Other,rituximab
Other,RL
Other,rnaKnockdown
Other,rnaOligonucleotides
Other,RNAs
Other,rnaSequenceAnalysis
Other,roboticSurgicalSystems
Other,roboticSystem
Other,robust
Other,robustSynthesisMethods
Other,robustTechnology
Other,rocCurveAnalysis
Other,role
Other,roleForPre-existingInborn-likeErrorsOfMetabolism
Other,roleOfCircularRnas
Other,roleOfEstrogens
Other,roleOfImage-basedTextureFeaturesAsNoninvasivePrognosticBiomarkers
Other,roleOfPdgf-b/pdgfr-betaAxisInRareTypesOfBreastCancers
Other,roleOfSupportOfferedByVirtualCommunitiesToBreastCancerPatients
Other,rolePlayedByPdgfFamilyMembersInNormalDevelopmentOfBreastTissueDespiteItsPotentPro-lymphangiogenicEffects
Other,roles
Other,RON
Other,ronReceptorTyrosineKinase
Other,roughly15000Cases
Other,roughly15000CasesPerYear
Other,routine
Other,routineProcedure
Other,routineUse
Other,routineUseByFoodAdministrationIn2002
Other,rs5743810ProAllele
Other,RT
Other,ruralCancerHospital
Other,ruralSetting
Other,S10
Other,S7
Other,safety
Other,salpingo-oophorectomy
Other,sameRangeAsCasesWithoutWavelength-dependentMeasurementErrors
Other,sample
Other,sampleSizes
Other,satisfied
Other,saudiArabianWomen
Other,scalable
Other,scan
Other,scarceReports
Other,scEnrichment
Other,scope
Other,score
Other,scPhenotype
Other,screened
Other,Screening
Other,screeningPrograms
Other,screeningStrategy
Other,screeningTools
Other,scrutinized
Other,SCs
Other,SD-CNN
Other,SE
Other,search
Other,searched
Other,second
Other,secondaryLymphoidTissueDevelopmentOfLymphocytesWithinMicrocompartmentsOfTissue
Other,secondaryLymphomatousInvolvement
Other,secondLargestHmo
Other,secondSurgery
Other,secondTumor
Other,secondValuedApproach
Other,secretion
Other,secretionOfTumorNecrosisFactor
Other,sectionLeads
Other,seen
Other,segmentationAlgorithm
Other,segments
Other,selected
Other,selectedOptimalFeatureSubsets
Other,selectedPatients
Other,selectedPopulationsOfAfricanPatients
Other,selectiveAccumulationOfFluorescentOsteopontinInVitroAndInVivo
Other,selectiveBinding
Other,selectPatientPopulations
Other,sensitive
Other,sensitiveCells
Other,sensitiveNano-genosensor
Other,sensor
Other,sentinelLymphNodeBiopsy
Other,sentinelNodeBiopsy
Other,separateClassificationModels
Other,sequelae
Other,serious
Other,serumCrust
Other,serumSamplesFromCancerPatients
Other,seValues
Other,sevenWomen
Other,severalHer2-targetedTherapies
Other,severalIndividuals
Other,severalIntelligentTechniques
Other,severalObjectives
Other,severalOtherGenes
Other,severalPatients
Other,severalTumorSuppressorGenesInLungCancerPatients
Other,severe
Other,severePneumopathy
Other,severeThreat
Other,sexes
Other,sexualityEvidence
Other,sexualityMoreEvidence
Other,shallowCnn
Other,shallow-CNN
Other,shanxiProvinceOfChina
Other,shaped
Other,shapes
Other,she
Other,shift
Other,shorterRadiotherapyRegimens
Other,short-termStrategy
Other,shouldAdministered
Other,shouldAnalyzed
Other,shouldCo-managed
Other,shouldCo-managedByCardiologist
Other,shouldConsideredInEventOfAbnormalImagingFindings
Other,shouldElaborated
Other,shouldEstablished
Other,shouldGiven
Other,shouldGivenToGeriatricOncology
Other,shouldPerformed
Other,shouldPerformedInAtRisk
Other,shouldProceede
Other,shouldProcessed
Other,shouldStaged
Other,shouldTested
Other,show
Other,shown
Other,sialicAcidExpression
Other,signalAmplificationStrategies
Other,signalIntensity
Other,signalTransductionMoleculesIncludingProteinKinaseC
Other,signatures
Other,significance
Other,significant
Other,significantAdvances
Other,significantAssociationBetweenRs5743810AllelicFrequency
Other,significantCausativeGenes
Other,significantChallenge
Other,significantConnection
Other,significantEnrichmentOfCdh1MutationsWithinEcDomainsInComparisonToCdh1MutationsAssociatedWithHdgc
Other,significantHigherRisk
Other,significantIncrease
Other,significantlyAssociated
Other,significantlyAssociatedWithSeveralHealthOutcomesForTargetChild6YearsLaterIncludingCertainInfections
Other,significantlyCorrelated
Other,significantlyCorrelatedWithOverallSurvival
Other,significantlyDecreased
Other,significantlyHigherPcrRatesThanPatientsWithLuminalTypes
Other,significantlyHigherThanInFamiliesOfNfpaPatients
Other,significantlyLower
Other,significantlyProlongedMedianPfs
Other,significantlyReduced
Other,significantlyUp-regulated
Other,significantlyYounger
Other,similar
Other,similarExperimentalParameters
Other,similarlyInPancreaticCancersHaveSuggestedAsDiagnosticBiomarker
Other,similarPfs
Other,similarSeriousAdverseEvents
Other,similarTowaveletFilter
Other,simpleLow-costAlternative
Other,simulatedBreastCancer
Other,simulatedInnerBreastTissue
Other,simulation
Other,simulationStudies
Other,singleMetastaticSite
Other,singleSmallIncision
Other,sister
Other,sites
Other,sixCirculatingMirnas
Other,size
Other,skeleton
Other,skullLesions
Other,small
Other,smallMoleculeInhibitors
Other,smallPopulation
Other,smallProportion
Other,SNPs
Other,soFarHasMainlyAssociatedWithMutationsInBrca1
Other,solidTumor
Other,solidTumors
Other,solubleMediators
Other,solved
Other,sometimesMistaken
Other,sonography
Other,sosReconstruction
Other,sosValues
Other,southernPortuguese
Other,sox9NucleusEntry
Other,SP
Other,spanishWomenWithLungCancer
Other,sparseCoding
Other,sparseCombinationOfRiemannianDictionaryAtoms
Other,spc24Knockdown
Other,SpCM
Other,specialEmphasisOnTheirDifferentialDiagnosis
Other,specificAreas
Other,specificCancerCell-relatedComponents
Other,specificCircumstances
Other,specificityImprovement
Other,specificSubtype
Other,specimen
Other,spectrum
Other,speed
Other,Speed-of-sound
Other,spindleCells
Other,SPIO
Other,splenicLymphocytes
Other,SRS
Other,ssessed
Other,ssessedByWoundHealingAssayinAddition
Other,stable
Other,stableDrug-carrierBinding
Other,stage
Other,stageIi
Other,stageIiiBreastCaner
Other,stageIv
Other,stagingSystems
Other,stained
Other,staining
Other,standard
Other,standardAxillarySurgery
Other,standardizedDataCollection
Other,standardizedImagingProtocol
Other,standardMethod
Other,standardOfCareAsFirst-lineTreatmentOfPatientsWithHer2-positiveAEvenInReal-worldSetting
Other,STAT1
Other,stat1RecruitmentToEralphaPromoterRegion
Other,state-of-the-artAlgorithms
Other,statisticalClassifiers
Other,statisticallyCorrelated
Other,statisticallySignificantValuesAt4Cells/7MlBlood
Other,status
Other,statusOfScreeningWomenWithDenseBreasts
Other,Stem-likeCells
Other,Steps
Other,stereotacticWire-guidedBiopsy
Other,stillDifficult
Other,strategies
Other,strategy
Other,stratification
Other,stromalExpression
Other,strong
Other,strongAssociation
Other,strongAssociationBetweenRs5743810AgainstRiskInSaudiArabianWomen
Other,strongContrast
Other,strongContrastWithImagingModalities
Other,strongFamilyHistoryOfCancer
Other,strongIndependentPrognosticFactor
Other,strongLinkage
Other,structureChanges
Other,studied
Other,Studies
Other,studiesFocused
Other,subacuteEffects
Other,subgroupOfMacroprolactinomas
Other,subgroupVariables
Other,subjectiveRisk
Other,subsequentAxillaryLymphNodeDissection
Other,subsequentCancerCounselingOfFemaleSurvivors
Other,subsequentLung/bronchusMalignancies
Other,subsequentlyAssessed
Other,subsequentMalignancies
Other,subsequentMalignanciesForLung/bronchusCancerWith13PercecntSurvivorsSufferedFromSubsequentMalignancies
Other,subsequentPrimaries
Other,subsequentRadiomics
Other,subset
Other,substantialDelayFromDiagnosisToTreatment
Other,substantialDiscordancesBetweenPrimaryTumors
Other,substantialImprovements
Other,substantialRacial/ethnicDisparity
Other,substantialSubsetOfTotalSample
Other,subtype
Other,subtyped
Other,subtypes
Other,subtype-specificPrognosticSignatures
Other,successfulFunctionalizationOfNanocompositeOfSpecificSequenceOfAminatedComplementaryOligonucleotideOfMirna-21
Other,successfullyUsed
Other,successOfSymmetricPositiveDefiniteMatrices
Other,suchLowIncidence
Other,suchStandardization
Other,suchSymptoms
Other,sufferingFromWoman'sDisease
Other,sufficient
Other,suggested
Other,suggesting
Other,SUM159PT
Other,summarised
Other,summarisedIn2018WorldCancerResearchFund/americanInstituteForCancerResearchReportGlobalPerspective
Other,summary
Other,supplementalScreening
Other,supplements
Other,support
Other,supportVectorMachine
Other,suppressionOfBreastCancer
Other,surfaceArea
Other,surgeon
Other,surgery
Other,surgicalOutcome
Other,surrogates
Other,surveillanceData
Other,surveillancePopulation-basedData
Other,survey
Other,Survival
Other,survivalData
Other,survivalDifferences
Other,survivalDistributions
Other,survivalOfCellsInVitroAndInVivo
Other,survivalPrediction
Other,survivalRate
Other,survivalRates
Other,survivalRatesOfLungCancerContinue
Other,survivalThanAdjuvantTherapy
Other,survivalTime
Other,survivalVariance
Other,suspected
Other,sustainedStableDisease
Other,sutegories
Other,Sutegorization
Other,suutaneousBreastTumor
Other,suvmax39
Other,SVM
Other,SVM-BRC
Other,sw-22
Other,switch
Other,switched
Other,symptom
Other,symptomaticWomen
Other,Symptoms
Other,synchrotronRadiation
Other,synchrotronSources
Other,syndrome
Other,syndromes
Other,synthesisMethods
Other,synthesized
Other,system
Other,systematicCharacterization
Other,systematicReview
Other,systematicSearch
Other,systemicChemotherapy
Other,systems
Other,T2
Other,t2bSutegory
Other,t2Category
Other,TAAs
Other,tackled
Other,tailoredConsiderations
Other,taiwanLongitudinalHealthInsuranceDatabase2005
Other,taken
Other,tamoxifen-resistanceInErCancerCells
Other,tangshanPeople
Other,tanUsage
Other,target
Other,targeted
Other,targetedImaging-guidedPhotothermal/chemoSynergisticTumorTherapyWithHighTherapeuticEfficacy
Other,targetedTherapies
Other,targetedTumorAccumulation
Other,Targeting
Other,targetingFxyd3-mediatedPathway
Other,targetVolume
Other,technique
Other,techniques
Other,tenfoldCross-validationMatthew
Other,terms
Other,termsOfClassification
Other,termsOfKyotoEncyclopediaOfGenes
Other,termsOfMechanism
Other,tertiarySexualHealthCenters
Other,test
Other,tested
Other,testing
Other,testingDataSet
Other,tests
Other,textureAnalysis
Other,textureFeatures
Other,that
Other,thatOfMir-511
Other,thatOfOtherCountries
Other,the
Other,their
Other,theirAdjacentMatchedTissues
Other,theirCardiotoxicities
Other,theirCare
Other,theirContraceptivePreferences
Other,theirEmergingRole
Other,theirExperiencesLivingWithSister
Other,theirInhibition
Other,theirInteractions
Other,theirInteractionsLikeGene-gene
Other,theirLimitedAccess
Other,theirLong-termSurvival
Other,theirOriginallyTargetedPopulationsOfBreastCancer
Other,theirOwnParticularity
Other,theirParticularity
Other,theirRisk
Other,theirSelection
Other,theirSurvival
Other,theirVariousness
Other,them
Other,thematicAnalysis
Other,themselves
Other,thenAdded
Other,thenClassifiedBySupportVectorMachines
Other,thenDefinedInReproductiveYears
Other,thenExploredByRocheCobasE601
Other,thenLinkedToTownshipFemaleBreastCancerIncidenceRateIn2000s
Other,thenShouldTestedForSpecificGeneMutationFound
Other,thenUsed
Other,thepresence
Other,therapeuticallyEffective
Other,therapeuticBenefits
Other,therapeuticEffectsInBreastCancer
Other,therapeuticTargetForPotentialTreatment
Other,Therapies
Other,therapy
Other,therebyFrequentlyNeglected
Other,thereforeAdministered
Other,thereforeApplied
Other,thereforeCentralTarget
Other,thereforeCriticalSignificance
Other,thereforeHasAppliedToEarlyIdentification
Other,thereforeRequired
Other,thereforeUrgentlyNeeded
Other,thereforeVeryPromisingStrategy
Other,theResulting
Other,these
Other,They
Other,third
Other,third-degree
Other,thirdInTermsOfSpecificMortality
Other,This
Other,those
Other,thoughtfulMultidisciplinaryPlanning
Other,three6-monthPeriods
Other,threeCases
Other,threeDifferentClusters
Other,threeDifferentUsMachines
Other,threeKinds
Other,threeKindsOfAlgorithms
Other,threeOverallSurvival
Other,threeParadigmaticExamples
Other,three-yearSurvivalRates
Other,thriceHigher
Other,thromboembolicEvents
Other,throughOptimizationTestsChosenAsOptimalConditions
Other,thusAimed
Other,thusCritical
Other,thusImportant
Other,thusMeaningful
Other,thusPotentialTherapeuticTarget
Other,thusPresented
Other,tightDoctor-patientCollaboration
Other,time
Other,timeOfTheirAppointmentwithDoctor
Other,times
Other,timingOfChemotherapyForBreastCancersWithDifferentMolecularBackgrounds
Other,tissueBiopsy
Other,tissues
Other,tissueStorageTime
Other,tissueTumors
Other,TIVAP
Other,t-MDS
Other,t-MN
Other,tnmStage
Other,tnmStaging
Other,tolerabilitytheApatinib
Other,tomography
Other,tool
Other,tools
Other,top10InformationalNeedContents
Other,total
Other,totalOf121Patients
Other,towaveletFilter
Other,township
Other,toxic
Other,tract'sMetastases
Other,traditionalPredictors
Other,training
Other,trajectoryMembership
Other,transcoelomic
Other,transcriptionFactorForkheadBoxC1
Other,Transcripts
Other,transferable
Other,transformed
Other,transitionProbabilities
Other,transport
Other,trastuzumab
Other,trastuzumab/pertuzumab/taxane
Other,trastuzumabInitiation
Other,trastuzumabTherapy
Other,trastuzumabTherapyForBreastCancer
Other,treated
Other,treatedWithCapecitabineMonotherapyAsThird-lineTherapy
Other,treatedWithIntraperitonealInjectionFor30Days
Other,treatment
Other,treatmentCompletion
Other,treatmentMoreAccessibleToBreastCancerPatients
Other,treatmentOfBreastCancer
Other,treatmentOfEuropeanPatients
Other,treatmentOfTriple-negativeBreastCancerWithConventionalChemotherapeuticAgents
Other,treatmentOutcomePrediction
Other,treatmentProtocols
Other,treatments
Other,treatmentTherapy
Other,treatmentWithWholeBrainRadiotherapy
Other,trend
Other,trendForLessRadicalSurgicalApproachesInBreastCancer
Other,trends
Other,trendsInUkCancerIncidenceByCancerSite
Other,trials
Other,trialsOfHer2-targetedTherapiesIn
Other,triple-negativeSubtypeMda-mb-231Cells
Other,trueRisk
Other,tumorAccumulation
Other,tumor-bearingMiceOfMcf-7BreastCancerCells
Other,tumorBurden
Other,tumorCells
Other,tumorEasily
Other,tumorFluid
Other,tumorGroups
Other,tumorGrowth
Other,tumorGrowthInExperimentalModels
Other,tumorigenesisOfBreastCancer
Other,tumorImaging
Other,tumorInformation
Other,tumorNecrosisFactor
Other,tumorNeoangiogenesisSimilarToBreastMagneticResonanceImaging
Other,tumorSamples
Other,tumorSite
Other,tumorSites
Other,tumorSite-specificInformation
Other,tumorSuppressorFunction
Other,tumorSuppressorFunctionOfP53InPathogenesisOfBreastCancer
Other,tumorSuppressorGene
Other,tumorSuppressorMir-10aInCells
Other,tumourigenesis
Other,tumourSpread
Other,twenty-twoPatients
Other,twoCases
Other,twoChlorambucilPlatinum
Other,twoGroups
Other,twoIndependentReviewers
Other,twoLargeBreastCancerDatabases
Other,twoMoieties
Other,twoPathways
Other,twoScales
Other,twoSutegories
Other,two-thirdsOfBreastCancerCases
Other,twoTumorGroups
Other,twoUncommonCasesOfDelayedBreastCancerRelapses
Other,twoYears
Other,type
Other,type160Patients
Other,type1Diabetes
Other,typical
Other,typicalFeaturesIncludingFibrocysticBreastDisease
Other,typicalHormone-dependentTumor
Other,typicalImagingPattern
Other,typicallyBilateral
Other,typicalWoman
Other,typicalWoman'sDisease
Other,Uganda
Other,ukCancerIncidence
Other,ultrasound
Other,ultrasound-guidedDiffuseOpticalTomography
Other,unbiasedRnaSequenceAnalysis
Other,Uncertainties
Other,unclear
Other,uncommon
Other,uncouplingOfInverseCorrelationBetweenBmi
Other,uncover
Other,undergoing
Other,underlying
Other,underlyingCauses
Other,underlyingIncrease
Other,understand
Other,understanding
Other,understandingOfEmergingConceptsOfTumorBiology
Other,understood
Other,understudied
Other,understudiedPattern
Other,underutilized
Other,underway
Other,undifferentiatedNeoplasticCells
Other,unenhancedMriTechniques
Other,uniqueFeatureInteractWithNucleicAcids
Other,uniqueProperties
Other,unitedKingdom
Other,unitedStates
Other,Univariate
Other,unknown
Other,unnecessaryRepeatBiopsies
Other,unnecessarySubsequentExaminations
Other,un-recognized
Other,unreported
Other,unusual
Other,unusualImmuneProfiles
Other,unusualPresentationOfSuperiorVenaCavaSyndrome
Other,update
Other,upregulated
Other,up-regulated
Other,upregulation
Other,upregulationOfE-cadherinExpressionLevels
Other,uptake
Other,uptakeOfTrastuzumab
Other,urgent
Other,urgentClinicalProblem
Other,urgentlyNeeded
Other,us
Other,usd$901
Other,Use
Other,used
Other,usedAtOurInstitutionForSelectPatientsWithGoodOutcomes
Other,useful
Other,usefulness
Other,useOfAdvancedImagingExaminations
Other,usExaminations
Other,Using
Other,usStandardization
Other,usualCare
Other,usuallyAssociated
Other,usuallyDiscoveredIncidentally
Other,usuallyLong-term
Other,usuallyPerformed
Other,uterine
Other,uterineTumors
Other,uterus
Other,utility
Other,Utilization
Other,utilized
Other,validated
Other,validatedAlgorithms
Other,Validation
Other,value
Other,valueOfErbeta-targetedTherapies
Other,values
Other,vap-1Expression
Other,vap-1ImmunohistochemicalStaining
Other,vap-1NegativeStaining
Other,vap-1Staining
Other,vap-1StainingResults
Other,variability
Other,variableMolecularMechanismsOfCarcinogenesis
Other,variables
Other,variants
Other,variation
Other,variousArtifactsIntroducedDuringSlidePreparation
Other,variousEnvironments
Other,variousImportantFunctions
Other,variousMethods
Other,variousNon-pharmacologicalAdjuvantTherapies
Other,variousOtherCancerInHumanBody
Other,variousStimuli
Other,varyingAmountsOfSolidComponents
Other,vdrExpression
Other,venaCavaSyndrome
Other,veryComplexDisease
Other,veryRareCases
Other,v-gCalciumChannelBindingAntibodies
Other,virtualReality
Other,visits
Other,visualInspection
Other,visualizedTheranosticsOfTumors
Other,vitalRole
Other,vitalRoles
Other,volume
Other,volumes
Other,volumetricMeasurementSystem
Other,vulnerability
Other,warranted
Other,water
Other,wavelengthConsistencyIndex
Other,ways
Other,We
Other,weak
Other,webOfSciencePsycinfo
Other,well-established
Other,well-establishedTreatment
Other,westernBlotAnalysis
Other,westernBlotting
Other,westernizedCountries
Other,whenActiveUse
Other,whenGiven
Other,whenIntegratedWithinCountry/region'sHealthPlan
Other,whenonlyAnalyzed
Other,whenPerformedBeforeMenopause
Other,whenSevere
Other,whenSuspected
Other,whereDeveloped
Other,whereFacilitatedBySurfaceModificationOfNps
Other,whereFormulated
Other,whereNeeded
Other,WHI
Other,widelyAcceptedAsStandardOfCareFollowingBreastConservation
Other,widelyExpressed
Other,widelyKnown
Other,widelyUsed
Other,widelyUtilized
Other,widerPopulationOfPatients
Other,widespreadInterest
Other,willDifferent
Other,willDifferentRegardingSubtypeAtDiagnosis
Other,willLeadToMortalityReductionsWithoutUsualScreeningHarms
Other,willTested
Other,willTestedThroughEuropeanMyPersonalBreastScreening
Other,willUsed
Other,willUsedAsReferences
Other,withandControllingForTreatmentDelays
Other,withFourier-domainReconstruction
Other,womenAcrossGlobe
Other,womenCarriers
Other,womenInWorld
Other,women'sCancerAccounting
Other,womenWithExtremelyDenseBreasts
Other,womenWithG
Other,womenWithMore70PercecntOfPatientsTreatedWithHormonalTherapy
Other,womenWorldwide
Other,wordCloud
Other,workflowConsistingOfImmunoaffinityPurification
Other,world
Other,worldwide
Other,worldwideHighestAge-standardizedBreastCancerIncidence
Other,worseOsThanT2aSutegory
Other,worseOutcome
Other,xenograftMice
Other,x-rayMammography
Other,year
Other,yearRfsrate
Other,years
Other,yetHasFirmlyEstablishedInClinicalPractice
Other,yetUnclear
Other,yoga
Other,younger
Other,youngerBreastCancerSurvivors
Other,youngerPeople
Other,youngestCohort
Other,youngMalePatients
Other,youngMen
Other,youngMexicanWomen
Other,youngPatients
Other,youngWomen
Other,youngWomenWithInvasiveLobularCarcinoma
Other,YS
Other,Zt/g4-MMAE
Pathogenic,pathogenicVariants
Pediatric,accurateDiagnosisInPediatricPatients
Pediatric,pediatricPatients
Pediatric,pediatricPopulation
Pediatric,shouldPerformedInPediatricPatients
PET/CT,f-fdgPet/ct
PET/CT,subgroupAnalysispleuroparenchymalAnomaliesRateDetectedOnF-fdgPet/ct
Plasticity,976PercecntSensitivity
Plasticity,bodyMassIndex
Plasticity,comparableToContrast-enhancedMriInTermsOfSensitivityAtFractionOfCost
Plasticity,discoveryOfBiochemicalSignaturesMeasuredByMassSpectrometry
Plasticity,highSensitivity
Plasticity,lowDiagnosticSensitivityForWomenWithDenseBreasts
Plasticity,mass
Plasticity,massInPosteriorFossaOfBrain
Plasticity,massMedia
Plasticity,massProduction
Plasticity,massSize
Plasticity,massSpectrometry
Plasticity,one-waySensitivityAnalyses
Plasticity,plasticity
Plasticity,sensitivity
Plasticity,sensitivityAnalysesresults
Plasticity,sensitivityOf786PercecntRespectively
Plasticity,sensitivityOfDrug-resistantCellsToChemotherapeutics
Plasticity,sensitivityOfMda-mb-468ToChemotherapeutics
Plasticity,tumorWeight
Plasticity,univariateSensitivityAnalysesresults
Plasticity,uterineMass
Polymorphisms,occurrenceOfPolymorphisms
Polymorphisms,polymorphisms
Polymorphisms,polymorphismsImportant
Polymorphisms,resultsOfIndividualVdrPolymorphisms
Polymorphisms,vdrPolymorphisms
Post-diagnosis,associationBetweenPost-diagnosisLow-doseAspirinUse
Post-diagnosis,associationBetweenPost-diagnosisUseOfLow-doseAspirin
Post-diagnosis,time-varyingPost-diagnosisLow-doseAspirinUse
Probe,fluorescenceMicroscopy
Probe,handheldProbeCapable
Probe,intravenousAdministrationOfOsteopontin-750Probe
Probe,nirProbe
Probe,nirProbeNir-sn-ggt
Probe,novelNear-infraredNirFluorescentProbe
Probe,osteopontin-basedProbe
Probe,oxidativeStressProbe
Probe,probe
Probe,probeNir-sn-ggt
Probe,remarkableEnzyme-activatedNirFluorescentProbeNir-sn-ggt
Probe,specificEralpha-targetedProbe
Probe,stressProbe
Procedures,interventionalProcedures
Procedures,procedures
Provision,2-groupRandomizedControlTrial
Provision,60ControlPatients
Provision,activation
Provision,activationOfOther
Provision,agreement
Provision,base
Provision,breastCancerControl
Provision,breastCancerControlEfforts
Provision,breastCancerControlEffortsForIdentification
Provision,cancerControlPlanning
Provision,canDetectedWithHelpOfVariousProfilingMethods
Provision,constitutiveActivationOfDownstreamSignalingPathway
Provision,control
Provision,controlTrial
Provision,criticalScientificBase
Provision,criticalScientificBaseForPrecisionMedicineInBreastCancer
Provision,currentFollow-up
Provision,cytokineFunctionsLeadingToDevelopmentOfCancers
Provision,directActingOralAnticoagulants
Provision,disturbance
Provision,effectsOfAnnexinA3OnBreastCancerBiologicalBehaviorInVivo
Provision,evenMorePersonalizedFollow-upSchedules
Provision,exercise
Provision,follow-up
Provision,follow-upSchemes
Provision,hasReducedThroughoutLastDecades
Provision,lastFourDecades
Provision,leadingCancerSitesInOlderMales
Provision,leadingCauseOfMorbidityWorldwideYetMethodsForEarlyDetection
Provision,littleHelp
Provision,localControl
Provision,medianFollow-upOf48Years
Provision,medianFollow-upOf9·
Provision,moreIntensiveFollow-up
Provision,oneYearOfDiseaseControlWithoutDeteriorationInHerEjectionFraction
Provision,overLastYearsHaveProposedAsBiomarkersForCancerDetection
Provision,pathologyForFurtherFollow-up
Provision,personalizedFollow-upSchemes
Provision,probablyTranscriptionalActivation
Provision,provision
Provision,rangingFromDiagnosisPhaseToControlOfDisease
Provision,screeningBehavior
Provision,secondLeadingCause
Provision,site-specificBindingLeadingToImprovedCancerTreatmentWithMinimalRisksToNormalCells
Provision,thusInRecentYearsDemand
Provision,unnecessaryFollow-upVisitsForWomenWithVeryLowRisks
Quantification,feasibleInProperlySelectedCasesWithAsymptomaticNeuromasAfterAccurateTissueSampling
Quantification,multidimensionalScaling
Quantification,observation
Quantification,quantification
Quantification,successfulQuantification
Quantification,successfulQuantificationOfCa15-3InSerumSamplesFromCancerPatients
Quantification,whole-tumorSamplingOfDiseaseBurden
Regions,differentFunctionRegions
Regions,enhancerRegions
Regions,sixteenRegionsOfKazakhstan
Relapse,better
Relapse,betterOs
Relapse,betterOutcomes
Relapse,betterOutcomeWithGoodNegativePredictiveValue
Relapse,betterPrognosis
Relapse,betterPrognosisInBl1Patients
Relapse,betterResults
Relapse,betterUnderstanding
Relapse,betterUnderstandingOfRisksAssociatedWithM
Relapse,breastCancerRelapse
Relapse,continuousPatternOfRelapse
Relapse,exit
Relapse,greaterthanorequalto10PercecntDecline
Relapse,medianTimeToCnsRelapseOf31Years
Relapse,mitoticExitOfPtx-pretreatedCells
Relapse,reductionOfRelapse
Relapse,relapse
Relapse,riskOfBreastRelapse
Relapse,withBetterDrugDeliveryPotentialOfNon-sphericalShapesHaveRecentlyInvestigated
Resection,Resection
Resistance,action
Resistance,activity
Resistance,activityOfCellProliferationInBreastCancerCells
Resistance,activityOfTransplantedTumors
Resistance,aggressiveCourseOfHer2Cancer
Resistance,anticoagulantChoice
Resistance,application
Resistance,applicationOfPhase-sensitiveTechniques
Resistance,associationsOfPhysicalActivityInGlobalHealthInBreastCancerSurvivors
Resistance,attenuatedCellGrowth
Resistance,bl1Cell
Resistance,bl1CellMda-mb-468
Resistance,breastCancerCellInvasion
Resistance,breastCancerCellMigration
Resistance,cancer-relatedEventsIncludingTumorCellMigration
Resistance,capabilitiesOfCellInvasion
Resistance,capacitance
Resistance,capacity
Resistance,capacityForEarlyDiagnosisOfBreastCancer
Resistance,Cell
Resistance,cellInvasion
Resistance,CellLines
Resistance,cellMigration
Resistance,characteristicsLikeCapacityForInvasion
Resistance,chemotherapyResistance
Resistance,choiceOfChemotherapyInBrca-associatedCancers
Resistance,choiceOfImmunohistochemicalTechniques
Resistance,conflict
Resistance,consistentWithBreastCancerCellResultsSignificantlyInhibited
Resistance,course
Resistance,drugResistance
Resistance,drugResistanceOf
Resistance,freshLeafEthanolicExtract-treatedMda-mb-231CellDeath
Resistance,greatPotentialOfClinicalApplication
Resistance,heterogeneousExpressionOfHumanEpidermalGrowthFactorReceptor2OnIndividualCancerCellSurface
Resistance,increasedCellApoptosis
Resistance,inhibitionOfCellProliferation
Resistance,leafMda-mb-231CellDeath
Resistance,lungCellCarcinomas
Resistance,mitochondrialTransmembranePotential-drivenRegulatedCellDeaths
Resistance,modestAnti-tumorActivity
Resistance,moreImportantlyCanNowComplementedByEmergingDeepLearningTechniquesForFurtherProcessAutomation
Resistance,multidrugResistance
Resistance,netvizzApplication
Resistance,panelOf25GenesInvolvedInMechanismsOfTargetedTreatmentResistanceIn16PrimaryBreastCancersDevelopedDuringTreatment
Resistance,panelOfCellLinesWithDifferentPhenotypes
Resistance,panelOfMonoclonalAntibodiesAgainstNewlyEstablishedCellLine
Resistance,physicalActivity
Resistance,physicalActivityInPatientsWithMetastaticBreastCancer
Resistance,potentAnticancerActivity
Resistance,potentialApplicationForDiagnosisOfCancerInFuture
Resistance,proliferationOfThreeCancerCellLinesWithLowIc
Resistance,resistance
Resistance,resistanceToExistingTherapies
Resistance,shouldOvercomeBeforeClinicalApplication
Resistance,significantAntiproliferativeActivityAgainstHumanTumorCellLines
Resistance,suppressionOfCellSurvival
Resistance,tamoxifenResistance
Resistance,tediousCountingCell
Resistance,theirApplication
Resistance,theirCytotoxicityAgainstTwoHumanTumorCellLines
Resistance,theirEffectsOnHumanBreastCancerMda-mb-231CellGrowthInhibition
Resistance,theirInterestingBiologicalActivity
Resistance,transcriptionalActivityOfHypoxia-inducibleFactor1
Resistance,transmembraneCellDeaths
Resistance,vitaminDActivity
Resistance,weakToStrongReactivityToOtherCellLines
Sarcomas,forty-twoHigh-gradeSarcomas
Sarcomas,high-gradeSarcomas
Sarcomas,softTissueSarcomas
Scoring,nuclearAtypiaScoring
Scoring,Scoring
Sequencing,appropriateSequencing
Sequencing,sequencing
Sequencing,therapeuticSequencing
Seroma,updateOnRiskFactorsForSeromaProductionAfterBreastCancerSurgery
Similarities,similarities
Similarities,similaritiesInInformationalNeedsByCancerType
Similarities,similaritiesOfInformationRequired
Skin,3GroupsBasedOnTertiarySolubleSt-2Level
Skin,alarmingLevelGlobally
Skin,aromataseInhibitor-inducedBoneLoss
Skin,at25HPost-injectionGreaterInTumorBedThanInKidneyRespectively
Skin,balfLevel
Skin,bone
Skin,clinicalSecondLevelExamination
Skin,contextOfTwoCasesOfBladder
Skin,cut-offBalfLevel
Skin,dichlorofluoresceinLevel
Skin,expressionLevel
Skin,geneExpressionLevel
Skin,growthOfCancerCellsInSkinOriginatingFromInternalCancer
Skin,itsExpressionLevel
Skin,level
Skin,levelExamination
Skin,mrnaExpressionLevelOfPcdh10
Skin,needForAwarenessOfMimicsOfBoneMetastasis
Skin,pax6OverexpressionIncreasingMmp2Andmmp9ExpressionAtMrnaLevel
Skin,significanceLevel
Skin,skinMetastases
Skin,skinMetastasis
Skin,skinOriginatingFromInternalCancer
Skin,solubleSt-2Level
Skin,st-2Level
Skin,twoCasesOfMimicsOfBoneMetastasis
Sleep,age
Sleep,ageGroups
Sleep,ageOf25Years
Sleep,ageOfTreatmentMethods
Sleep,currentUsersOfLongerDuration
Sleep,documentationOfPatientAge
Sleep,duringAgeAssociatedWithIncreaseOf8MoreFemaleBreastCancerCasesPer100000DuringAge50-54
Sleep,fastDayBefore
Sleep,furthermoreDiagnosedWithPaAtEarlierAgeThanPatientsWithNegativeFamilyHistory
Sleep,hadDiagnosedWithBreastCancerAtEarlyAge
Sleep,importanceOfProactivelyAddressingFertility
Sleep,influenceOfSleepQualityOnPmInPatientsTreatedWithHt
Sleep,inTotalDiagnosedUnderAgeOf50
Sleep,medianAge
Sleep,medianAgeOf50
Sleep,medianDiagnosisAge
Sleep,otherAgeGroups
Sleep,possibleCorrelationsWithClinicalStatusIncludingAge
Sleep,secondDecadeAfterDiagnosis
Sleep,significantlyYoungerAge
Sleep,stillSeriousHealthProblemIn21stCenturySubjectToManyResearch
Sleep,stratifyingForAge
Sleep,threeYearsBeforeAge64Years
Sleep,womenOfReproductiveAge
Sleep,youngAge
Sleep,youngerAge
Species,children
Species,Fisher
Species,human
Species,mice
Species,nudeMice
Species,participants
Species,patient
Species,patients
Species,People
Species,woman
Species,women
Sprays,ddtSprays
Sprays,increaseWithNumberOfSprays
Stigmatization,mostStigmatization
Stigmatization,sexualStigmatizationOfM
Stigmatization,stigmatization
Surgeons,Surgeons
Surgeries,complexSurgeries
Transmembrane,mitochondrialTransmembranePotential
Traumatic,traumaticBreastNeuromas
Troponins,cardiacTroponins
Troponins,troponins
Users,12331Non-nsaidUsers
Users,12331Users
Users,non-nsaidUsers
Users,users